Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
  • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

• PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR)
• the present disclosure is directed to modulating pyruvate kinase, including novel compounds useful as PKR activators.
• PK Pyruvate Kinase converts phosphoenolpyruvate (PEP) and adenosine diphosphate (ADP) to pyruvate and adenosine triphosphate (ATP), respectively, which is the final step in glycolysis.
• PEP phosphoenolpyruvate
• ADP adenosine diphosphate
• ATP adenosine triphosphate
• four PK isoforms are expressed by two structural genes.
• the PKLR gene encodes PKR and PKL tissue specific isoforms expressed in erythroid cells and liver, respectively.
• the PKM gene codes for isoforms PKM1, expressed in brain and skeletal muscle, and PKM2 (M2-type pyruvate kinase), expressed in fetal and most adult tissues except erythroid cells (Takenaka et al, Eur J Biochem 1991, 198:101).
• PKD pyruvate kinase deficiency
• an autosomal recessive disorder which is the most frequent enzymatic defect of the glycolytic pathway in erythrocytes.
• Over 200 different mutations have been identified on the structural PKLR gene (Bianchi et al, Blood Cells Mol Dis 2000, 26:47).
• PKD patients are heterozygous with two different mutant alleles, but homozygous mutations have also been described (Diez et al. Blood 2005, 106:1851).
• Clinical symptoms of PKD vary considerably from mild to severe anemia. Mutations can reduce PK enzymatic activity or decrease PK protein stability.
• PKR diseases related to PKR
• diseases related to PKR such as PKD
• PKR activating small molecules PKR exists in both a dimeric and tetrameric state, but functions most efficiently as a tetramer.
• Small molecules have been shown to be capable of shifting the equilibrium of PKR to the tetrameric (most active) form, providing a mechanistic rationale for their use as therapy for PKD-associated hemolytic anemia.
• PKR activating compounds useful for treating diseases and disorders associated with modulation of PKR and/or PKM2.
• PKR Activating Compounds disclosed herein can increase the activity of wild-type and mutant PK enzymes in biochemical assays disclosed herein (e.g., Example 47). Data from PKR Activating Compounds herein illustrate the potential for these compounds to restore glycolytic pathway activity in patients with PK deficiency, with the goal of providing clinical benefit. Compounds disclosed herein are useful in the treatment of diseases or disorders associated with pyruvate kinase function.
• the PKR Activating Compounds disclosed can be useful in the treatment of diseases, including but not limited to, PKD, sickle cell disease (SCD) (e.g., sickle cell anemia), and thalassemia (e.g., beta-thalassemia).
• SCD sickle cell disease
• thalassemia e.g., beta-thalassemia
• the compounds can be useful in the treatment of other indications related to pyruvate kinase modulation.
• One aspect of the present disclosure relates to compounds of Formula I (e.g., compounds of Formula (I) identified as PKR Activating Compounds using the Luminescence Assay Protocol of Example 47):
• Y is a bond,–(CR 5 R 5’ ) t –,–NR 5 (CR 5 R 5' ) t –, or–O—;
• each R 1 , R 1’ , R 2 , and R 2’ is independently–H,–(C 1 -C 6 )alkyl,–(C 2 -C 6 )alkenyl,–
• R 1 and R 1’ , or R 2 and R 2’ together with the atom to which they are attached, can combine to form a–(C 3 -C 8 )cycloalkyl ring, heterocycle, (C 5 -C 8 )spirocycle or 5-to 8-membered spiroheterocycle;
• R 1 and R 2 together with the atoms to which they are attached, can combine to form a– (C 3 -C 8 )cycloalkyl or a 3-to 8-membered heterocycle;
• R 3 is independently–H,–(C 1 -C 6 )alkyl,–(C 2 -C 6 )alkenyl,–(C 2 -C 6 )alkynyl,–(C 3 - C 8 )cycloalkyl,–(C 4 -C 8 )cycloalkenyl, heterocyclyl, aryl, heteroaryl,–S(O) 2 R 5 ,–S(O) 2 NR 5 R 5’ ,– S(O)R 5 ,–S(O)NR 5 R 5’ ,–C(O)R 5 , or–C(O)OR 5 , wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more substituents selected from the group consisting of oxo, halogen,–CN,–R 5 ,–OR 5 ,–SR 5 ,
• R 2 and R 3 together with the atoms to which they are attached, can combine to form a 5- to 8-membered heterocyclic ring;
• R 1 and R 3 together with the atoms to which they are attached, can combine to form a 5- to 8-membered heterocyclic ring;
• R 4 is–H,–(C 1 -C 6 )alkyl,–(C 2 -C 6 )alkenyl,–(C 2 -C 6 )alkynyl,–(C 3 -C 8 )cycloalkyl,–(C 4 - C 8 )cycloalkenyl, heterocyclyl, aryl, heteroaryl, halogen,–CN,–OR 5 ,–SR 5 ,–NO 2 ,–NR 5 R 5’ ,– S(O) 2 R 5 ,–S(O) 2 NR 5 R 5’ ,–S(O)R 5 ,–S(O)NR 5 R 5’ ,–NR 5 S(O) 2 R 5’ ,–NR 5 S(O)R 5’ ,–C(O)R 5 , or– C(O)OR 5 , wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl,
• each R 5 and R 5' is independently, at each occurrence,–H,–(C 1 -C 6 )alkyl,–(C 2 -C 6 )alkenyl, –(C 2 -C 6 )alkynyl,–(C 3 -C 8 )cycloalkyl,–(C 4 -C 8 )cycloalkenyl, heterocyclyl, aryl, heteroaryl, halogen,–CN,–OR 6 ,–SR 6 ,–NO 2 ,–NR 6 R 6’ ,–S(O) 2 R 6 ,–S(O) 2 NR 6 R 6’ ,–S(O)R 6 ,–S(O)NR 6 R 6’ ,– NR 6 S(O) 2 R 6’ ,–NR 6 S(O)R 6’ ,–C(O)R 6 , or–C(O)OR 6 , wherein each alkyl, alkenyl, alkynyl, cycloalkyl
• R 5 on adjacent atoms together with the atoms to which they are attached form an aryl ring optionally substituted with one or more R 6 ; or two R 5 on adjacent atoms together with the atoms to which they are attached form a heteroaryl ring optionally substituted with one or more R 6 ; or two R 5 on adjacent atoms together with the atoms to which they are attached form a (C 3 -C 8 )cycloalkyl ring optionally substituted with one or more R 6 ; or two R 5 on adjacent atoms together with the atoms to which they are attached form a heterocycloalkyl ring optionally substituted with one or more R 6 ;
• R 5' on adjacent atoms together with the atoms to which they are attached form an aryl ring optionally substituted with one or more R 6 ; or two R 5' on adjacent atoms together with the atoms to which they are attached form a heteroaryl ring optionally substituted with one or more R 6 ; or two R 5' on adjacent atoms together with the atoms to which they are attached form a (C 3 -C 8 )cycloalkyl ring optionally substituted with one or more R 6 ; or two R 5' on adjacent atoms together with the atoms to which they are attached form a heterocycloalkyl ring optionally substituted with one or more R 6 ;
• each R 6 and R 6' is independently, at each occurrence,–H,–(C 1 -C 6 )alkyl,–(C 2 -C 6 )alkenyl, –(C 2 -C 6 )alkynyl,–(C 3 -C 8 )cycloalkyl,–(C 4 -C 8 )cycloalkenyl, heterocyclyl, aryl, heteroaryl, halogen,–CN,–OR 7 ,–SR 7 ,–NO 2 ,–NR 7 R 7’ ,–S(O) 2 R 7 ,–S(O) 2 NR 7 R 7’ ,–S(O)R 7 ,–S(O)NR 7 R 7’ ,– NR 7 S(O) 2 R 7’ ,–NR 7 S(O)R 7’ ,–C(O)R 7 , or–C(O)OR 7 , wherein each alkyl, alkenyl, alkynyl, cycloalkyl
• each R 7 and R 7' is independently, at each occurrence,–H,–(C 1 -C 6 )alkyl,–(C 2 -C 6 )alkenyl, –(C 2 -C 6 )alkynyl,–(C 3 -C 8 )cycloalkyl,–(C 4 -C 8 )cycloalkenyl, heterocyclyl, aryl, heteroaryl, halogen,–CN,–OH,–SH,–NO 2 ,–NH 2 ,–S(O) 2 H,–S(O) 2 NH 2 ,–S(O)H,–S(O)NH 2 ,–NHS(O) 2 H, –NHS(O)H,–C(O)H, or–C(O)OH, wherein each alkyl, alkenyl, alkynyl, cycloalkyl,
• t 0, 1, 2, or 3.
• each occurrence of R 7 and R 7’ disclosed herein for each of R 6 , R 6 ', R 8 , R 8' , R 9 , R 9’ , R 10 , R 10’ , R 11 , and R 11’ is independently selected from any of the possible recited values of R 7 and R 7' .
• the value R 7 may have a different value for each of R 6 , R 6 ', R 8 , R 8' , R 9 , R 9’ , R 10 , R 10’ , R 11 , and R 11’ unless otherwise indicated herein.
• the present disclosure also provides compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein:
• R 1 is selected from the group consisting of–H,–(C 1 -C 6 )alkyl, 6-membered aryl, and 6- membered heteroaryl;
• R 1’ is selected from the group consisting of–H and–(C 1 -C 6 )alkyl
• R 1 and R 1’ together with the atom to which they are attached, can combine to form a– (C 3 -C 8 )cycloalkyl or a 3- to 8-membered heterocycle;
• each R 2 and R 2’ is independently selected from the group consisting of –H and–(C 1 - C 6 )alkyl;
• R 3 is–H or–(C 1 -C 6 )alkyl
• R 1 and R 3 together with the atoms to which they are attached, can combine to form a 5- to 8-membered heterocyclic ring, optionally fused to an aryl or heteroaryl ring;
• R 4 is 6- to 10-membered aryl or 6- to 10-membered heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of oxo, halogen,– CN,–R 5 ,–OR 5 , or–NR 5 R 5’ ;
• each R 5 and R 5' is independently, at each occurrence,–H,–(C 1 -C 6 )alkyl optionally substituted with one or more halogen, -OR 6 , or–NR 6 R 6’ ;
• R 5 on adjacent atoms of R 4 together with the atoms to which they are attached optionally form a 5- or 6-membered heterocycloalkyl ring optionally substituted with one or more R 6 ;
• each R 6 is independently, at each occurrence,–H,–(C 1 -C 6 )alkyl,–(C 2 -C 6 )alkenyl,–(C 2 - C 6 )alkynyl,–(C 3 -C 8 )cycloalkyl,–(C 4 -C 8 )cycloalkenyl, heterocyclyl, aryl, heteroaryl, halogen,– CN, –OR 7 , –SR 7 , –NO 2 , –NR 7 R 7’ , –S(O) 2 R 7 , –S(O) 2 NR 7 R 7’ , –S(O)R 7 , –S(O)NR 7 R 7’ , – NR 7 S(O) 2 R 7’ ,–NR 7 S(O)R 7’ ,–C(O)R 7 , or–C(O)OR 7 , wherein each alkyl, alkenyl, alkynyl,
• each R 7 and R 7' is independently, at each occurrence,–H,–(C 1 -C 6 )alkyl,–(C 2 -C 6 )alkenyl, –(C 2 -C 6 )alkynyl, –(C 3 -C 8 )cycloalkyl, –(C 4 -C 8 )cycloalkenyl, heterocyclyl, aryl, heteroaryl, halogen,–CN,–OH,–SH,–NO 2 ,–NH 2 ,–S(O) 2 H,–S(O) 2 NH 2 ,–S(O)H,–S(O)NH 2 ,–NHS(O) 2 H, –NHS(O)H, –C(O)H, or –C(O)OH, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, or heteroaryl is optionally
• each R 1 and R 1’ is independently selected from the group consisting of–H,–(C 1 -C 6 )alkyl, aryl, and heteroaryl, wherein each alkyl, aryl, or heteroaryl is optionally substituted with one or more substituents selected from the group consisting of oxo,
• R 1 and R 1’ together with the atom to which they are attached, can combine to form a– (C 3 -C 8 )cycloalkyl ring, heterocycle, (C 5 -C 8 )spirocycle or 5-to 8-membered spiroheterocycle; each R 2 and R 2’ is independently selected from the group consisting of–H and–(C 1 - C 6 )alkyl, optionally substituted with one or more substituents selected from the group consisting of oxo, halogen, -CN, -R 5 , -OR 5 , -SR 5 , -NO 2 , -NR 5 R 5’ , -S(O) 2 R 5 ,–
• R 3 is independently–H,–(C 1 -C 6 )alkyl,–(C 2 -C 6 )alkenyl,–(C 2 -C 6 )alkynyl,–(C 3 - C 8 )cycloalkyl,–(C 4 -C 8 )cycloalkenyl, heterocyclyl, aryl, heteroaryl,–S(O) 2 R 5 ,–S(O) 2 NR 5 R 5’ ,– S(O)R 5 ,–S(O)NR 5 R 5’ ,–C(O)R 5 , or–C(O)OR 5 , wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more substituents selected from the group consisting of oxo, halogen,–CN,–R 5 ,–OR 5 ,–SR 5 ,
• R 4 is 6- to 10-membered aryl or 6- to 10-membered heteroaryl, each optionally substituted with one or more substituents selected from the group consisting of oxo, halogen,– CN,–R 5 ,–OR 5 or–NR 5 R 5’ ;
• each R 5 and R 5' is independently, at each occurrence,–H,–(C 1 -C 6 )alkyl, -OR 6 , or– NR 6 R 6’ ;
• R 5 on adjacent atoms of R 4 together with the atoms to which they are attached form a 5- or 6-membered heterocycloalkyl ring optionally substituted with one or more R 6 ;
• each R 6 is independently, at each occurrence,–H or–(C 1 -C 6 )alkyl
• each R 8 , R 8' , R 9 , R 9’ , R 10 , R 10’ , R 11 , and R 11’ is independently, at each occurrence,–H.
• R 4 is 6-membered aryl or heteroaryl substituted with two–R 5 , selected from the group consisting of–OR 6 and–NR 6 R 6’ , on adjacent atoms of R 4 , that together with the atoms to which they are attached form a heterocycloalkyl ring fused to R 4 that is optionally substituted with one or more R 6 , selected from the group consisting of–H and– (C 1 -C 6 )alkyl.
• compositions comprising a compound of Formula I and a pharmaceutically acceptable carrier.
• the disclosure provides methods of treating a disease or disorder associated with modulation of pyruvate kinase (PKR) which comprises administering to a patient in need thereof an effective amount of a compound of Formula I.
• PLR pyruvate kinase
• the present disclosure also provides methods of treating a disease associated with decreased activity of PKR in a subject in need thereof which comprises administering to the subject an effective amount of a compound of Formula I.
• Another aspect of the present disclosure is a method of activating PKR, comprising contacting PKR with an effective amount of a compound of Formula I.
• Further aspects of the present disclosure include: methods of increasing the lifetime of red blood cells; methods of regulating 2,3-diphosphoglycerate levels in blood; and methods of regulating ATP levels in blood; each of the foregoing methods comprising administering to a subject in need thereof an effective amount of a compound of Formula I.
• Another aspect of the present disclosure provides methods of treating hereditary non- spherocytic hemolytic anemia comprising administering to a subject in need thereof an effective amount of a compound of Formula I.
• Also provided herein are methods of treating a disease or disorder associated with increased 2,3 diphosphoglycerate levels comprising administering to a subject in need thereof an effective amount of a compound of Formula I.
• Another aspect of the disclosure provided herein includes methods of treating a disease or disorder associated with decreased ATP levels comprising administering to a subject in need thereof an effective amount of a compound of Formula I.
• a further aspect of the present disclosure includes methods of treating sickle cell anemia comprising administering to a subject in need thereof a therapeutically effective amount of any of Formula I.
• a further aspect of the present disclosure includes methods of treating hemolytic anemia comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I.
• Another aspect of the present disclosure includes methods of treating beta thalassemia comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I.
• FIG. 1 shows an exemplary dose-response curve for compounds disclosed herein.
• Dose-response curves may be generated using the standard four parameter fit algorithm of ActivityBase XE Runner to determine MAX%Fold, MIN%Fold, slope and AC 50 .
• MAX%Fold is the highest % fold increase observed at any concentration of compound
• MIN%Fold is the lowest % fold increase observed at any concentration of compound.
• the AC 50 value for a compound is the concentration ( ⁇ M) corresponding to the midway between the maximum and minimum values of the four parameter logistic curve fit (i.e., at which the % fold increase along the four parameter logistic curve fit is halfway between MAX%Fold and MIN%Fold (% Fold Midpoint).
• %Fold@1.54 ⁇ M Another useful parameter for evaluating compounds of this disclosure is %Fold@1.54 ⁇ M, which is the % fold increase at a compound concentration of 1.5 ⁇ M (e.g., 1.54 ⁇ M).
• X-axis and y-axis not necessarily to scale.
• the present disclosure relates to compounds and compositions that are capable of activating the activity of PKR and/or PKM2.
• the disclosure features methods of treating a disease or disorder in which PKR and/or PKM2 plays a role by administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
• the methods of the present disclosure can be used in the treatment of a variety of PKR and/or PKM2 dependent diseases and disorders by activating the activity of PKR and/or PKM2 enzymes.
• PKR and PKM2 Activation of PKR and PKM2 provides a novel approach to the treatment of diseases including, but not limited to, PKD, SCD (e.g., sickle cell anemia), and thalassemia (e.g., beta-thalassemia.
• PKD PKD
• SCD sickle cell anemia
• thalassemia e.g., beta-thalassemia.
• the PKR Activating Compounds disclosed herein can be useful for the treatment of hereditary blood disorders related to pyruvate kinase activity, including PKD and SCD.
• an alkyl group that is optionally substituted can be a fully saturated alkyl chain (e.g., a pure hydrocarbon).
• the same optionally substituted alkyl group can have substituents in place of one or more hydrogen atoms. For instance, it can, at any point along the chain be bounded to a halogen atom, a hydroxyl group, or any other substituent described herein.
• substituents used in the optional substitution of the described groups include, without limitation, halogen, oxo, -OH, -CN, -COOH, -CH 2 CN, -O-(C 1 -C 6 )alkyl, (C 1 -C 6 )alkyl, (C 1 - C 6 )alkoxy, (C 1 -C 6 )haloalkyl, (C 1 -C 6 )haloalkoxy, -O-(C 2 -C 6 )alkenyl, -O-(C 2 -C 6 )alkynyl, (C 2 - C 6 )alkenyl, (C 2 -C 6 )alkynyl, -OP(O)(OH) 2 , -OC(O)(C 1 -C 6 )alkyl,
• the term“substituted” means that the specified group or moiety bears one or more suitable substituents wherein the substituents may connect to the specified group or moiety at one or more positions.
• an aryl substituted with a cycloalkyl may indicate that the cycloalkyl connects to one atom of the aryl with a bond or by fusing with the aryl and sharing two or more common atoms.
• the term“partially unsaturated” refers to a ring moiety that includes at least one double or triple bond.
• the term“partially unsaturated” is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties, as herein defined.
• aryl refers to cyclic, aromatic hydrocarbon groups that have 1 to 3 aromatic rings having a total of 5 to 14 ring atoms, including monocyclic or bicyclic groups such as phenyl, biphenyl or naphthyl. Where containing two aromatic rings (bicyclic, etc.), the aromatic rings of the aryl group may be joined at a single point (e.g., biphenyl), or fused (e.g., naphthyl). The aryl group may be optionally substituted by one or more substituents, e.g., 1 to 5 substituents, at any point of attachment.
• substituents include, but are not limited to, -halogen, -O-(C 1 -C 6 )alkyl, (C 1 -C 6 )alkyl, -O-(C 2 - C 6 )alkenyl, -O-(C 2 -C 6 )alkynyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, -OH, -OP(O)(OH) 2 , -OC(O)(C 1 - C 6 )alkyl, -C(O)(C 1 -C 6 )alkyl, -OC(O)O(C 1 -C 6 )alkyl, -NH 2 , NH((C 1 -C 6 )alkyl), N((C 1 -C 6 )alkyl) 2 , - S(O) 2 -(C 1 -C 6 )alkyl, -S(O)
• the substituents can themselves be optionally substituted.
• the aryl groups herein defined may have an unsaturated or partially saturated ring fused with a fully unsaturated ring.
• Exemplary ring systems of these aryl groups include, but are not limited to, phenyl, biphenyl, naphthyl, anthracenyl, phenalenyl, phenanthrenyl, indanyl, indenyl, tetrahydronaphthalenyl, tetrahydrobenzoannulenyl, and the like.
• heteroaryl means a monovalent monocyclic or polycyclic aromatic radical of 5 to 24 ring atoms, containing one or more ring heteroatoms selected from the group consisting of N, O, and S, the remaining ring atoms being C.
• Heteroaryl as herein defined also means a bicyclic heteroaromatic group wherein the heteroatom is selected from the group consisting of N, O, and S.
• the aromatic radical is optionally substituted independently with one or more substituents described herein.
• Examples include, but are not limited to, furyl, thienyl, pyrrolyl, pyridyl, pyrazolyl, pyrimidinyl, imidazolyl, isoxazolyl, oxazolyl, oxadiazolyl, pyrazinyl, indolyl, thiophen-2-yl, quinolyl, benzopyranyl, isothiazolyl, thiazolyl, thiadiazole, indazole, benzimidazolyl, thieno[3,2-b]thiophene, triazolyl, triazinyl, imidazo[1,2-b]pyrazolyl, furo[2,3-c]pyridinyl, imidazo[1,2-a]pyridinyl, indazolyl, pyrrolo[2,3- c]pyridinyl, pyrrolo[3,2-c]pyridinyl, pyrazolo[3,4-c]pyri
• heteroaryl groups herein defined may have an unsaturated or partially saturated ring fused with a fully unsaturated ring.
• exemplary ring systems of these heteroaryl groups include indolinyl, indolinonyl, dihydrobenzothiophenyl, dihydrobenzofuran, chromanyl, thiochromanyl, tetrahydroquinolinyl, dihydrobenzothiazine, 3,4-dihydro-1H-isoquinolinyl, 2,3-dihydrobenzofuran, indolinyl, indolyl, and dihydrobenzoxanyl.
• Halogen or“halo” refers to fluorine, chlorine, bromine, or iodine.
• Alkyl refers to a straight or branched chain saturated hydrocarbon containing 1-12 carbon atoms.
• Examples of a (C 1 -C 6 )alkyl group include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, neopentyl, and isohexyl.
• An alkyl group may be substituted by one or more substituents.
• Alkoxy refers to a straight or branched chain saturated hydrocarbon containing 1- 12 carbon atoms containing a terminal“O” in the chain, e.g., -O(alkyl).
• alkoxy groups include without limitation, methoxy, ethoxy, propoxy, butoxy, t-butoxy, or pentoxy groups.
• alkylene or“alkylenyl” refers to a divalent alkyl radical. Any of the above mentioned monovalent alkyl groups may be an alkylene by abstraction of a second hydrogen atom from the alkyl. As herein defined, alkylene may also be a C 1 -C 6 alkylene. An alkylene may further be a C 1 -C 4 alkylene.
• Typical alkylene groups include, but are not limited to, -CH 2 -, - CH(CH 3 )-, -C(CH 3 ) 2 -, -CH 2 CH 2 -, -CH 2 CH(CH 3 )-, -CH 2 C(CH 3 ) 2 -, -CH 2 CH 2 CH 2 -,
• Cycloalkyl or“carbocyclyl” means monocyclic or polycyclic saturated rings containing 3-18 carbon atoms.
• Examples of cycloalkyl groups include, without limitations, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptanyl, cyclooctanyl, norboranyl, norborenyl, bicyclo[2.2.2]octanyl, or bicyclo[2.2.2]octenyl and derivatives thereof.
• a C 3 -C 8 cycloalkyl is a cycloalkyl group containing between 3 and 8 carbon atoms.
• a cycloalkyl group can be fused (e.g., decalin) or bridged (e.g., norbornane).
• a cycloalkyl group may be substituted by one or more substituents.
• Heterocyclyl or“heterocycloalkyl” means 5- to 7-membered monocyclic or 7- to 10-membered polycyclic rings containing carbon and heteroatoms taken from oxygen, nitrogen, or sulfur, where such rings are either saturated or partially unsaturated.
• the heterocycloalkyl ring structure may be substituted by one or more substituents. The substituents can themselves be optionally substituted.
• heterocyclyl rings include, but are not limited to, oxetanyl, azetadinyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, oxazolinyl, oxazolidinyl, thiazolinyl, thiazolidinyl, pyranyl, thiopyranyl, tetrahydropyranyl, dioxalinyl, piperidinyl, morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S-dioxide, piperazinyl, azepinyl, oxepinyl, diazepinyl, tropanyl, oxazolidinonyl, and homotropanyl.
• hydroxyalkyl means an alkyl group as defined above, where the alkyl group is substituted with one or more OH groups.
• hydroxyalkyl groups include HO- CH 2 -, HO-CH 2 -CH 2 - and CH 3 -CH(OH)-.
• haloalkyl refers to an alkyl group, as defined herein, which is substituted with one or more halogen. Examples of haloalkyl groups include, but are not limited to, trifluoromethyl, difluoromethyl, pentafluoroethyl, trichloromethyl, etc.
• haloalkoxy refers to an alkoxy group, as defined herein, which is substituted with one or more halogen.
• haloalkoxy groups include, but are not limited to, trifluoromethoxy, difluoromethoxy, pentafluoroethoxy, trichloromethoxy, etc.
• cyano as used herein means a substituent having a carbon atom joined to a nitrogen atom by a triple bond, i.e., -C ⁇ N.
• “Spirocycloalkyl” or“spirocyclyl” means carbogenic bicyclic ring systems with both rings connected through a single atom.
• the ring can be different in size and nature, or identical in size and nature. Examples include spiropentane, spirohexane, spiroheptane, spirooctane, spirononane, or spirodecane.
• One or both of the rings in a spirocycle can be fused to another carbocyclic, heterocyclic, aromatic, or heteroaromatic ring.
• a (C 5 -C 12 )spirocycloalkyl is a spirocycle containing between 5 and 12 carbon atoms. One or more of the carbon atoms can be substituted with a heteroatom.
• spiroheterocycloalkyl or“spiroheterocyclyl” is understood to mean a spirocycle wherein at least one of the rings is a heterocycle (e.g., at least one of the rings is furanyl, morpholinyl, or piperadinyl).
• the term "isomer” refers to compounds that have the same composition and molecular weight but differ in physical and/or chemical properties. The structural difference may be in constitution (e.g., geometric isomers) or in the ability to rotate a plane of polarized light (stereoisomers). With regard to stereoisomers, the compounds of Formula (I) may have one or more asymmetric carbon atoms and may occur as racemates, racemic mixtures or as individual enantiomers or diastereomers.
• compositions comprising an effective amount of a disclosed compound and a pharmaceutically acceptable carrier.
• “Pharmaceutically acceptable salts” are well known in the art. For example, S. M. Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1–19, incorporated herein by reference.
• Representative pharmaceutically acceptable salts include, e.g., water-soluble and water-insoluble salts, such as acetate, amsonate (4,4- diaminostilbene-2,2-disulfonate), benzenesulfonate, benzonate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, calcium, calcium edetate, camsylate, carbonate, chloride, citrate, clavulariate, dihydrochloride, edetate, edisylate, estolate, esylate, fumerate, fiunarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexafluorophosphate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, magnesium, mal
• a "patient” or“subject” is a mammal, e.g., a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or non-human primate, such as a monkey, chimpanzee, baboon, or rhesus.
• an "effective amount" when used in connection with a compound is an amount effective for treating or preventing a disease in a subject as described herein.
• carrier encompasses carriers, excipients, and diluents and means a material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material, involved in carrying or transporting a pharmaceutical agent from one organ, or portion of the body, to another organ, or portion of the body of a subject.
• treating refers to improving at least one symptom of the subject's disorder. Treating includes curing, improving, or at least partially ameliorating the disorder.
• disorder is used in this disclosure to mean, and is used interchangeably with, the terms disease, condition, or illness, unless otherwise indicated.
• administer refers to either directly administering a disclosed compound, a pharmaceutically acceptable salt of a disclosed compound or a composition to a subject, a pharmaceutically acceptable salt of a compound, or a composition to a subject, which can form an equivalent amount of active compound within the subject's body.
• cancer includes, but is not limited to, the following cancers: bladder cancer, breast cancer (e.g., ductal carcinoma), cervical cancer (e.g., squamous cell carcinoma), colorectal cancer (e.g., adenocarcinoma), esophageal cancer (e.g., squamous cell carcinoma), gastric cancer (e.g., adenocarcinoma, medulloblastoma, colon cancer, choriocarcinoma, squamous cell carcinoma), head and neck cancer, hematologic cancer (e.g., acute lymphocytic anemia, acute myeloid leukemia, acute lymphoblastic B cell leukemia, anaplastic large cell lymphoma, B-cell lymphoma, Burkitt’s lymphoma, chronic lymphocytic leukemia, chronic eosinophillic leukemia/hypereosinophillic syndrome, chronic myeloid leukemia,
• bladder cancer e.g
• “PKR Activating Compound” refers to a compound having one or more of the following characteristics when tested according to the Luminescence Assay Protocol of Example 47 below: (1) an AC 50 value of less than 40 ⁇ M; (2) a maximum % Fold (MAX%Fold) value of greater than 75%; and/or (3) a % Fold value at 1.54 ⁇ M compound concentration (%Fold@1.54 ⁇ M) of at least 75%.
• the Luminescence Assay Protocol of Example 47 is performed with wild type (wt) PKR, G332S mutant form of PKR or R510Q mutant form of PKR.
• the PKR Activating Compound is a compound of Formula (I). In some embodiments, the PKR Activating Compound has: (1) an AC 50 value of less than 0.1 ⁇ M, 0.1-1.0 ⁇ M, or 1.01-40 ⁇ M; (2) a MAX%Fold of 75%-250%, 251-500%, or 75%-500%; and/or (3) a %Fold@1.54 ⁇ M of 75%- 250%, 251-500%, or 75%-500%.
• a PKR Activating Compound has (1) an AC 50 value of less than 1.0 ⁇ M; (2) a MAX%Fold of 75%-500%; and/or (3) a %Fold@1.54 ⁇ M of 75%-500%. In some embodiments, a PKR Activating Compound has (1) an AC 50 value of less than 1.0 ⁇ M; (2) a MAX%Fold of 75%-500%; and/or (3) a %Fold@1.54 ⁇ M of 75%- 500%, obtained in the Luminescence Assay Protocol with any one or more of wild type PKR (wt), G332S mutant form of PKR, or R510Q mutant form of PKR.
• the PKR Activating Compound has (1) an AC 50 value of less than 1.0 ⁇ M; (2) a MAX%Fold of 75%-500%; and/or (3) a %Fold@1.54 ⁇ M of 75%-500%, obtained in the Luminescence Assay Protocol with wild type PKR (wt). In some embodiments, the PKR Activating Compound has (1) an AC 50 value of less than 1.0 ⁇ M; (2) a MAX%Fold of 75%-500%; and/or (3) a %Fold@1.54 ⁇ M of 75%-500%, obtained in the Luminescence Assay Protocol with any one or both of G332S mutant form of PKR or R510Q mutant form of PKR.
• the compounds of the disclosure may contain asymmetric or chiral centers, and, therefore, exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of the disclosure, such as those which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, as well as mixtures thereof, including racemic mixtures, form part of the present disclosure.
• the assay results may reflect the data collected for the racemic form, the enantiomerically pure form, or any other form in terms of stereochemistry.
• the compounds of Formula (I) are enantiomers.
• the compounds are the (S)-enantiomer.
• the compounds are the (R)- enantiomer.
• the compounds of Formula (I) may be (+) or (-) enantiomers.
• Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as, for example, by chromatography and/or fractional crystallization.
• Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers.
• an appropriate optically active compound e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride
• converting e.g., hydrolyzing
• some of the compounds of the disclosure may be atropisomers (e.g., substituted biaryls) and are considered as part of this disclosure.
• Enantiomers can also
• the present disclosure embraces all geometric and positional isomers (such as, for example, 4-pyridyl and 3-pyridyl).
• a compound of the disclosure incorporates a double bond or a fused ring, both the cis- and trans- forms, as well as mixtures, are embraced within the scope of the disclosure.
• the substituent may be in the E or Z configuration, unless otherwise indicated.
• the cycloalkyl substituent may have a cis- or trans configuration, unless otherwise indicated.
• the present disclosure relates to compounds or pharmaceutically acceptable salts thereof, capable of activating PKR and/or PKM2, which are useful for the treatment of diseases and disorders associated with modulation of a PKR and/or PKM2 enzyme.
• the disclosure further relates to compounds, or pharmaceutically acceptable salts thereof, which are useful for activating PKR and/or PKM2. COMPOUNDS OF THE DISCLOSURE
• R 1 , R 1’ , R 2 , R 2’ , R 3 , R 4 , R 8 , R 8’ , R 9 , R 9’ , R 10 , R 10’ , R 11 , and R 11’ are as defined above and described in classes and subclasses herein, both singly and in combination.
• each occurrence of R 7 and R 7' disclosed herein for each of R 6 , R 6 ', R8, R 8' , R 9 , R 9’ , R 10 , R 10’ , R 11 , and R 11’ is independently selected from any of the possible recited values of R 7 and R 7' .
• the value R 7 may bave a different for each of R 6 , R 6 ', R 8 , R 8' , R 9 , R 9’ , R 10 , R 10’ , R 11 , and R 11’ unless otherwise indicated herein.
• the compounds of Formula I have an AC 50 value ⁇ 40 ⁇ M for PKR activity determined by a luminescence assay (e.g., that described in Example 47, below). In some embodiments, the compounds of Formula I have an AC 50 value ⁇ 1.0 ⁇ M for PKR activity determined by a luminescence assay (e.g., that described in Example 47, below). In some embodiments, the compounds of Formula I have an AC 50 value ⁇ 0.1 ⁇ M for PKR activity determined by a luminescence assay (e.g., that described in Example 47, below).
• the compounds of Formula I are of the Formula (Ia):
• R 1 , R 1’ , R 2 , R 2’ , R 3 , R 4 , R 8 , R 8’ , R 9 , R 9’ , R 10 , R 10’ , R 11 , and R 11’ are as defined above and described in classes and subclasses herein, both singly and in combination.
• the compounds of Formula I are of the Formula (Ib):
• R 1 , R 1’ , R 2 , R 2’ , R 3 , R 4 , R 8 , R 8’ , R 10 , and R 10’ are as defined above and described in classes and subclasses herein, both singly and in combination.
• the compounds of Formula I are of the Formula (Ic):
• R 1 , R 1’ , R 2 , R 2’ , R 3 , and R 4 are as defined above and described in classes and subclasses herein, both singly and in combination.
• each R 1 , R 1’ , R 2 , and R 2’ is independently–H,–(C 1 -C 6 )alkyl, aryl, or heteroaryl, wherein each alkyl, aryl, or heteroaryl is optionally substituted with one or more -OR 5 ;
• R 1 and R 1’ together with the atom to which they are attached, can combine to form a– (C 3 -C 8 )cycloalkyl ring;
• R 3 is–H or–(C 1 -C 6 )alkyl
• R 1 and R 3 together with the atoms to which they are attached, can combine to form a 5- to 8-membered heterocyclic ring, optionally fused to an aryl ring;
• R 4 is aryl or heteroaryl, wherein each aryl or heteroaryl is optionally substituted with one or more substituents selected from the group consisting of–R 5 and–OR 5 ;
• each R 5 is independently–H or–(C 1 -C 6 )alkyl, wherein each alkyl is optionally substituted with one or more halogen;
• each R 6 is–(C 1 -C 6 )alkyl.
• each R 1 , R 1’ , R 2 , and R 2’ is independently–H, phenyl, pyridyl, ethyl, or methyl optionally substituted with–OR 5 ;
• R 1 and R 1’ together with the atom to which they are attached, can combine to form a cyclopropyl ring;
• R 3 is–H or methyl
• R 1 and R 3 together with the atoms to which they are attached, can combine to form a tetrahydrofuran, tetrahydropyran, 2,3-dihydrobenzofuran, or morpholine;
• R 4 is phenyl, pyridyl, benzothiazolyl, benzofuranyl, or benzoxazolyl, wherein each phenyl, pyridyl, or benoxazolyl is optionally substituted with one or two substituents selected from the group consisting of–R 5 and–OR 5 ;
• each R 5 is independently–H or methyl optionally substituted with two or more halogen; or two R 5 on adjacent atoms together with the atoms to which they are attached form a heterocycloalkyl ring, comprising two heteroatoms selected from the group consisting of O and N, optionally substituted with one or two R 6 ; and
• each R 6 is methyl.
• the compounds of Formula I are of the Formula (Id-1):
• R 1 is–(C 1 -C 6 )alkyl,–(C 2 -C 6 )alkenyl,–(C 2 -C 6 )alkynyl,–(C 3 -C 8 )cycloalkyl,–(C 4 - C 8 )cycloalkenyl, heterocyclyl, aryl, heteroaryl, halogen,–CN,–OR 5 ,–SR 5 ,–NO 2 ,–NR 5 R 5’ ,– S(O) 2 R 5 ,–S(O) 2 NR 5 R 5’ ,–S(O)R 5 ,–S(O)NR 5 R 5’ ,–NR 5 S(O) 2 R 5’ ,–NR 5 S(O)R 5’ ,–C(O)R 5 , or– C(O)OR 5 , wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl
• each R 2 and R 2’ is independently–H,–(C 1 -C 6 )alkyl,–(C 2 -C 6 )alkenyl,–(C 2 -C 6 )alkynyl,– (C 3 -C 8 )cycloalkyl,–(C 4 -C 8 )cycloalkenyl, heterocyclyl, aryl, heteroaryl, halogen,–CN,–OR 5 ,– SR 5 ,–NO 2 ,–NR 5 R 5’ ,–S(O) 2 R 5 ,–S(O) 2 NR 5 R 5’ ,–S(O)R 5 ,–S(O)NR 5 R 5’ ,–NR 5 S(O) 2 R 5’ ,– NR 5 S(O)R 5’ ,–C(O)R 5 , or–C(O)OR 5 , wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalken
• R 2 and R 2’ together with the atom to which they are attached, can combine to form– (C 3 -C 8 )cycloalkyl ring, heterocycle, (C 5 -C 8 )spirocycle or 5-to 8-membered spiroheterocycle; or R 1 and R 2 , together with the atoms to which they are attached, can combine to form a– (C 3 -C 8 )cycloalkyl or a 3-to 8-membered heterocycle;
• R 3 is independently–H,–(C 1 -C 6 )alkyl,–(C 2 -C 6 )alkenyl,–(C 2 -C 6 )alkynyl,–(C 3 - C 8 )cycloalkyl,–(C 4 -C 8 )cycloalkenyl, heterocyclyl, aryl, heteroaryl,–S(O) 2 R 5 ,–S(O) 2 NR 5 R 5’ ,– S(O)R 5 ,–S(O)NR 5 R 5’ ,–C(O)R 5 , or–C(O)OR 5 , wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more substituents selected from the group consisting of oxo, halogen,–CN,–R 5 ,–OR 5 ,–SR 5 ,
• R 2 and R 3 together with the atoms to which they are attached, can combine to form a 5- to 8-membered heterocyclic ring;
• R 1 and R 3 together with the atoms to which they are attached, can combine to form a 5- to 8-membered heterocyclic ring, optionally fused to an aryl or heteroaryl ring.
• the compounds of Formula (Id-1) are of the Formula (Ia-1):
• R 1 , R 2 , R 2’ , R 3 , R 4 , R 8 , R 8’ , R 9 , R 9’ , R 10 , R 10’ , R 11 , and R 11’ are as defined above and described in classes and subclasses herein, both singly and in combination.
• the compounds of Formula (Id-1) are of the Formula (Ib-1):
• R 1 , R 2 , R 2’ , R 3 , R 4 , R 8 , R 8’ , R 10 , and R 10’ are as defined above and described in classes and subclasses herein, both singly and in combination.
• the compounds of Formula (Id-1) are of the Formula (Ic-1):
• R 1 , R 2 , R 2’ , R 3 , and R 4 are as defined above and described in classes and subclasses herein, both singly and in combination.
• the com ounds of Formula I are of the Formula (Id-2):
• R 1 is–(C 1 -C 6 )alkyl,–(C 2 -C 6 )alkenyl,–(C 2 -C 6 )alkynyl,–(C 3 -C 8 )cycloalkyl,–(C 4 - C 8 )cycloalkenyl, heterocyclyl, aryl, heteroaryl, halogen,–CN,–OR 5 ,–SR 5 ,–NO 5
• each R 2 and R 2’ is independently–H,–(C 1 -C 6 )alkyl,–(C 2 -C 6 )alkenyl,–(C 2 -C 6 )alkynyl,– (C 3 -C 8 )cycloalkyl,–(C 4 -C 8 )cycloalkenyl, heterocyclyl, aryl, heteroaryl, halogen,–CN,–OR 5 ,– SR 5 ,–NO 2 ,–NR 5 R 5’ ,–S(O) 2 R 5 ,–S(O) 2 NR 5 R 5’ ,–S(O)R 5 ,–S(O)NR 5 R 5’ ,–NR 5 S(O) 2 R 5’ ,– NR 5 S(O)R 5’ ,–C(O)R 5 , or–C(O)OR 5 , wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalken
• R 2 and R 2’ together with the atom to which they are attached, can combine to form– (C 3 -C 8 )cycloalkyl ring, heterocycle, (C 5 -C 8 )spirocycle or 5-to 8-membered spiroheterocycle; or R 1 and R 2 , together with the atoms to which they are attached, can combine to form a– (C 3 -C 8 )cycloalkyl or a 3-to 8-membered heterocycle;
• R 3 is independently–H,–(C 1 -C 6 )alkyl,–(C 2 -C 6 )alkenyl,–(C 2 -C 6 )alkynyl,–(C 3 - C 8 )cycloalkyl,–(C 4 -C 8 )cycloalkenyl, heterocyclyl, aryl, heteroaryl,–S(O) 2 R 5 ,–S(O) 2 NR 5 R 5’ ,– S(O)R 5 ,–S(O)NR 5 R 5’ ,–C(O)R 5 , or–C(O)OR 5 , wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more substituents selected from the group consisting of oxo, halogen,–CN,–R 5 ,–OR 5 ,–SR 5 ,
• R 2 and R 3 together with the atoms to which they are attached, can combine to form a 5- to 8-membered heterocyclic ring; and or R 1 and R 3 , together with the atoms to which they are attached, can combine to form a 5- to 8-membered heterocyclic ring, optionally fused to an aryl or heteroaryl ring.
• the compounds of Formula (Id-2) are of the Formula (Ia-2):
• R 1 , R 2 , R 2’ , R 3 , R 4 , R 8 , R 8’ , R 9 , R 9’ , R 10 , R 10’ , R 11 , and R 11’ are as defined above and described in classes and subclasses herein, both singly and in combination.
• the compounds of Formula (Id-2) are of the Formula (Ib-2):
• R 1 , R 2 , R 2’ , R 3 , R 4 , R 8 , R 8’ , R 10 and R 10’ are as defined above and described in classes and subclasses herein, both singly and in combination.
• the compounds of Formula (Id-2) are of the Formula (Ic-2):
• R 1 , R 2 , R 2’ , R 3 , and R 4 are as defined above and described in classes and subclasses herein, both singly and in combination.
• R 1 and R 1’ are each independently hydrogen, optionally substituted–(C 1 -C 6 )alkyl (e.g., methyl optionally substituted with -OR 5 , or ethyl), optionally substituted aryl (e.g., phenyl), or optionally substituted heteroaryl (e.g., pyridyl), or R 1 and R 1’ are taken together with the atoms to which they are attached to form an optionally substituted -(C 3 -C 4 )cycloalkyl (e.g., cyclopropyl). In some embodiments, R 1 and R 1’ are both hydrogen.
• R 1 and R 1’ are both optionally substituted–(C 1 -C 6 )alkyl. In some embodiments, one of R 1 and R 1’ is optionally substituted–(C 1 -C 6 )alkyl, optionally substituted aryl, or optionally substituted heteroaryl. In some embodiments, one of R 1 and R 1’ is optionally substituted aryl or optionally substituted heteroaryl. In some embodiments, one of R 1 and R 1’ is hydrogen. In some embodiments, one of R 1 and R 1’ is optionally substituted–(C 1 -C 6 )alkyl. In some embodiments, one of R 1 and R 1’ is optionally substituted aryl.
• one of R 1 and R 1’ is optionally substituted heteroaryl.
• R 1 and R 1’ are taken together with the atoms to which they are attached to form an optionally substituted–(C 3 -C 4 )cycloalkyl.
• R 1 is optionally substituted–(C 1 -C 6 )alkyl (e.g., methyl optionally substituted with - OR 5 , or ethyl), optionally substituted aryl (e.g., phenyl), or optionally substituted heteroaryl (e.g., pyridyl).
• R 1 is optionally substituted –(C 1 -C 6 )alkyl.
• R 1 is optionally substituted aryl.
• R 1 is optionally substituted heteroaryl.
• R 2 and R 2’ are each independently hydrogen or optionally substituted–(C 1 -C 6 )alkyl (e.g., methyl). In some embodiments, R 2 and R 2’ are both hydrogen. In some embodiments, R 2 and R 2’ are both optionally substituted–(C 1 -C 6 )alkyl. In some embodiments, one of R 2 and R 2’ is hydrogen. In some embodiments, one of R 2 and R 2’ is optionally substituted–(C 1 -C 6 )alkyl.
• R 3 is hydrogen or optionally substituted–(C 1 -C 6 )alkyl (e.g., methyl). In some embodiments, R 3 is hydrogen. In some embodiments, R 3 is optionally substituted–(C 1 - C 6 )alkyl.
• R 3 and one of R 1 or R 1’ are taken together with the atoms to which they are attached to form an optionally substituted 5-6- membered heterocyclic ring, optionally fused to an aryl ring (e.g., tetrahydrofuran, tetrahydropyran, 2,3-dihydrobenzofuran, or morpholine).
• aryl ring e.g., tetrahydrofuran, tetrahydropyran, 2,3-dihydrobenzofuran, or morpholine.
• R 3 and R 1 combine to form an optionally substituted heterocyclic ring selected from the group consisting of teterahydrofuran, tetrahydropyran, morpholine, dioxane, and 2,3-dihydrobenzofuran.
• R 3 and R 1 are taken together with the atoms to which they are attached to form an optionally substituted 5-6-membered heterocyclic ring (e.g., tetrahydrofuran, tetrahydropyran, 2,3-dihydrobenzofuran, or morpholine).
• an optionally substituted 5-6-membered heterocyclic ring e.g., tetrahydrofuran, tetrahydropyran, 2,3-dihydrobenzofuran, or morpholine.
• R 3 and R 1 combine to form an optionally substituted heterocyclic ring selected from the group consisting of teterahydrofuran, tetrahydropyran, morpholine, dioxane, and 2,3-dihydrobenzofuran.
• R 1 and R 1’ are each independently hydrogen or optionally substituted phenyl or pyridyl; R 2 and R 2’ are each independently hydrogen; and R 3 is hydrogen or optionally substituted–(C 1 -C 6 )alkyl.
• R 1 and R 1’ are each independently hydrogen or optionally substituted phenyl or pyridyl; R 2 and R 2’ are each independently hydrogen; and R 3 is hydrogen.
• one of R 1 and R 1’ is hydrogen and the other is optionally substituted phenyl; R 2 and R 2’ are each independently hydrogen; and R 3 is hydrogen or optionally substituted–(C 1 - C 6 )alkyl.
• one of R 1 and R 1’ is hydrogen and the other is optionally substituted pyridyl; R 2 and R 2’ are each independently hydrogen; and R 3 is hydrogen or optionally substituted–(C 1 -C 6 )alkyl.
• R 1 and R 1’ are each independently hydrogen or optionally substituted phenyl or pyridyl; R 2 and R 2’ are each independently hydrogen or optionally substituted–(C 1 -C 6 )alkyl; and R 3 is hydrogen.
• one of R 1 and R 1’ is hydrogen and the other is optionally substituted phenyl; R 2 and R 2’ are each independently hydrogen or optionally substituted–(C 1 -C 6 )alkyl; and R 3 is hydrogen.
• one of R 1 and R 1’ is hydrogen and the other is optionally substituted pyridyl;
• R 2 and R 2’ are each independently hydrogen or optionally substituted–(C 1 -C 6 )alkyl; and
• R 3 is hydrogen.
• R 1 is optionally substituted phenyl or pyridyl; R 2 and R 2’ are each independently hydrogen; and R 3 is hydrogen or optionally substituted–(C 1 -C 6 )alkyl. In some embodiments, R 1 is optionally substituted phenyl or pyridyl; R 2 and R 2’ are each independently hydrogen; and R 3 is hydrogen.
• R 1 is optionally substituted phenyl or pyridyl; R 2 and R 2’ are each independently hydrogen or optionally substituted–(C 1 -C 6 )alkyl; and R 3 is hydrogen. In some embodiments, R 1 is optionally substituted phenyl; R 2 and R 2’ are each independently hydrogen or optionally substituted–(C 1 -C 6 )alkyl; and R 3 is hydrogen. In some embodiments, R 1 is optionally substituted pyridyl; R 2 and R 2’ are each independently hydrogen or optionally substituted–(C 1 -C 6 )alkyl; and R 3 is hydrogen.
• R 4 is optionally substituted aryl (e.g., phenyl) or heteroaryl (e.g., pyridyl, benzofuranyl, benzoxazolyl, or benzothiazolyl).
• aryl e.g., phenyl
• heteroaryl e.g., pyridyl, benzofuranyl, benzoxazolyl, or benzothiazolyl
• the aryl or heteroaryl is optionally substituted with one or more substituents selected from the group consisting of oxo, halogen,–CN,–R 5 ,–OR 5 ,–SR 5 ,–NO 2 ,–NR 5 R 5’ ,–S(O) 2 R 5 ,–S(O) 2 NR 5 R 5’ ,– S(O)R 5 ,–S(O)NR 5 R 5’ ,–NR 5 S(O) 2 R 5’ ,–NR 5 S(O)R 5’ ,–C(O)R 5 , and–C(O)OR 5 .
• the aryl or heteroaryl is optionally substituted with one or more substituents selected from the group consisting of halogen, oxo,–CN,–R 5 ,–OR 5 ,–S(O) 2 NR 5 R 5’ ,– S(O)NR 5 R 5’ , and–C(O)R 5 .
• aryl or heteroaryl is optionally substituted with one or more substituents selected from the group consisting of–R 5 and–OR 5 .
• R 4 is aryl or heteroaryl optionally substituted with one or more –R 5 or -OR 5 , or two R 5 on adjacent atoms, together with the atoms to which they are attached, form a heterocycloalkyl ring, optionally substituted with one or more R 6 .
• R 4 including any substitution thereof, is selected from the group consisting of:
• R 4 is 6-membered aryl or heteroaryl substituted with two–R 5 , selected from the group consisting of–OR 6 and–NR 6 R 6’ , on adjacent atoms of R 4 , that together with the atoms to which they are attached form a heterocycloalkyl ring fused to R 4 that is optionally substituted with one or more R 6 , selected from the group consisting of–H and–(C 1 -C 6 )alkyl.
• each R 5 is independently -H, -(C 1 -C 6 )alkyl (e.g., methyl, optionally substituted with one or more halogen), halogen,–CN,–OR 6 ,–SR 6 ,–NO 2 ,–NR 6 R 6’ ,– S(O) 2 R 6 ,–S(O) 2 NR 6 R 6’ ,–S(O)R 6 ,–S(O)NR 6 R 6’ ,–NR 6 S(O) 2 R 6’ ,–NR 6 S(O)R 6’ ,–C(O)R 6 , or– C(O)OR 6 .
• each R 5 is independently -H or optionally substituted -(C 1 - C 6 )alkyl.
• two R 5 on adjacent atoms, together with the atoms to which they are attached form an aryl ring optionally substituted with one or more R 6 .
• two R 5 on adjacent atoms, together with the atoms to which they are attached form a heteroaryl ring optionally substituted with one or more R 6 .
• two R 5 on adjacent atoms together with the atoms to which they are attached form a (C 3 -C 8 )cycloalkyl ring optionally substituted with one or more R 6 .
• two R 5 on adjacent atoms together with the atoms to which they are attached form a heterocycloalkyl ring optionally substituted with one or more R 6 .
• each R 6 is independently -H, -(C 1 -C 6 )alkyl (e.g., methyl), halogen,–CN,–OR 7 ,–SR 7 ,–NO 2 ,–NR 7 R 7’ ,–S(O) 2 R 7 ,–S(O) 2 NR 7 R 7’ ,–S(O)R 7 ,–S(O)NR 7 R 7’ ,– NR 7 S(O) 2 R 7’ ,–NR 7 S(O)R 7’ ,–C(O)R 7 , or–C(O)OR 7 .
• R 6 is -(C 1 -C 6 )alkyl.
• Y is a bond
• Y is–CR 5 R 5' –.
• Y is–NR 5 (CR 5 R 5' ) t –.
• Y is–O–.
• Nonlimiting examples of the compounds of the disclosure include:
• the compounds of Formula (I) may be prepared by methods known in the art of organic synthesis as set forth in part by the following synthetic schemes. In the schemes described below, it is well understood that protecting groups for sensitive or reactive groups are employed where necessary in accordance with general principles of chemistry. Protecting groups are manipulated according to standard methods of organic synthesis (T. W. Greene and P. G. M. Wuts, "Protective Groups in Organic Synthesis", Third edition, Wiley, New York 1999). These groups are removed at a convenient stage of the compound synthesis using methods that are readily apparent to those skilled in the art. The selection processes, as well as the reaction conditions and order of their execution, shall be consistent with the preparation of compounds of Formula (I).
• a stereocenter exists in the compounds of Formula (I).
• a compound When a compound is desired as a single enantiomer or diastereomer, it may be obtained by stereospecific synthesis or by resolution of the final product or of any convenient intermediate.
• enantiomerically pure compounds of Formula (I) can be prepared using enantiomerically pure chiral building blocks.
• racemic mixtures of the final compounds or a racemic mixture of an advanced intermediate can be subjected to chiral purification as described herein below to deliver the desired enantiomerically pure intermediates or final compounds.
• each individual enantiomer can be carried on separately to deliver the final enantiomerically pure compounds of Formula (I).
• Resolution of the final product, an intermediate, or a starting material may be effected by any suitable method known in the art. See, for example, "Stereochemistry of Organic Compounds" by E. L. Eliel, S. H. Wilen, and L. N. Mander (Wiley-lnterscience, 1994). The absolute stereochemistry of compounds obtained by chiral resolution or chiral purification may or may not be determined.
• Enantiomerically pure compounds with undetermined absolute stereochemistry have been drawn as a single enantiomer chosen arbitrarily and are marked with an asterisk (*) at the chiral carbon herein.
• the compounds described herein may be made from commercially available starting materials or synthesized using known organic, inorganic, and/or enzymatic processes.
• the compounds of the present disclosure can be prepared in a number of ways well known to those skilled in the art of organic synthesis.
• compounds of the present disclosure can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereof as appreciated by those skilled in the art.
• Preferred methods include but are not limited to those methods described in the synthetic examples below.
• PKR Activating Compounds can be identified using the Luminescence Assay Protocol described in Example 47.
• the PKR Activating Compounds can be selected by obtaining and analyzing data from a dose-response curve for a compound in accordance with the Luminescence Assay Protocol.
• FIG. 1 shows an exemplary dose-response curve for compounds disclosed herein.
• the values of AC 50 and MAX%Fold are independent of each other (i.e., the value of one does not affect the other).
• PKR Activating Compounds can be selected based on the % Fold increase at a given concentration of compound (e.g., 1.54 ⁇ M) in the Luminescence Assay Protocol.
• the % Fold increase at a given concentration is a value which will be impacted by both the potency (AC 50 ) and activity (MAX%Fold).
• the PKR Activating Compound can be selected as a compound of Formula (I) having a % Fold value at 1.54 ⁇ M concentration of compound (%Fold@1.54 ⁇ M) of at least 75% (e.g., 75%-500%, 75%-250%, or 250%-500%) in an assay (e.g., the Luminescense Assay of Example 47) using a PKR enzyme (e.g., wild type PKR enzyme, or a clinically relevant mutant PKR, such as PKR G332S or PKR R510Q).
• a PKR enzyme e.g., wild type PKR enzyme, or a clinically relevant mutant PKR, such as PKR G332S or PKR R510Q.
• PKR Activating Compounds have a %Fold@1.54 ⁇ M of at least 75% (e.g., 75%-500% or 250%-500%) obtained using the Luminescence Assay Protocol of Example 47.
• PKR Activating Compounds can be identified in accordance with Example 47 by a method comprising the steps of (a) incubating a mixture of phosphoenolpyruvic acid (PEP) and PKR enzyme (e.g., wild type PKR or a clinically relevant PKR mutant enzyme) with a test compound at a concentration of 1.54 ⁇ M; (b) adding adenosine-5’-diphosphate (ADP) and a kinase luminescence reporter composition (e.g., Kinase Glo Plus) to the mixture in step (a) under conditions effective to induce luminescence in the presence of a test compound that is a PKR Activating Compound; (c) measuring the luminescence values of the mixture obtained in step (b); (d) determining the %Fold@1.54 ⁇ M value for the test compound; and (e) identifying the test compound as a PKR Activating Compound when the test compound has a %Fold@1.54 ⁇
• the present disclosure relates to a method of activating PKR, including methods of treating a disease or disorder in a patient by administering a therapeutically effective amount of a PKR Activating Compound disclosed herein.
• the method can comprise administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (I).
• the disease or disorder is selected from the group consisting of PKD, SCD (e.g., sickle cell anemia), and thalassemia (e.g., beta- thalassemia).
• a method of teating a patient diagnosed with a disease, selected from the group consisting of PKD, SCD, and thalassemia comprises administering a therapeutically effective amount of a compound disclosed herein, including a therapeutically effective amount of a PKR Activating Compound of Formula (I).
• a method of treating PKD comprises administering a therapeutically effective amount of a compound disclosed herein, including a PKR Activating Compound of Formula (I).
• a method of treating SCD comprises administering a therapeutically effective amount of a compound disclosed herein, including a PKR Activating Compound of Formula (I).
• a method of treating thalassemia comprises administering a therapeutically effective amount of a compound disclosed herein, including a PKR Activating Compound of Formula (I).
• the method comprises administering a therapeutically effective amount of a compound of Formula (I) for the treatment of a patient diagnosed with a condititon selected from the group consisting of: hereditary non-spherocytic hemolytic anemia, hemolytic anemia (e.g., chronic hemolytic anemia caused by phosphoglycerate kinase deficiency), hereditary spherocytosis, hereditary elliptocytosis, abetalipoproteinemia (or Bassen-Kornzweig syndrome), paroxysmal nocturnal hemoglobinuria, acquired hemolytic anemia (e.g., congenital anemias (e.g., enzymopathies)), or anemia of chronic diseases.
• a condititon selected from the group consisting of: hereditary non-spherocytic hemolytic anemia, hemolytic anemia (e.g., chronic hemolytic anemia caused by phosphoglycerate kinase deficiency),
• the disease or disorder is hereditary non-sperocytic hemolytic anemia.
• the disease or disorder is SCD (e.g., sickle cell anemia) or thalassemia (e.g., beta-thalassemia).
• the disease or disorder is hemolytic anemia (e.g., in a patient diagnosed with PKD).
• the disease or disorder is beta thalassemia.
• the disease or disorder is SCD.
• Another aspect of the disclosure relates to of the use of a PKR Activating Compound for treating a disease or disorder associated with modulation of PKR and/or PKM2.
• the present disclosure also relates to the use of an activator of PKR and/or PKM2 for the preparation of a medicament used in the treatment of a disease or condition, wherein the medicament comprises a compound of Formula (I).
• the present disclosure relates to the use of an activator of PKR and/or PKM2 for the preparation of a medicament used in the treatment of a disease or condition mediated by PKR and/or PKM2, wherein the medicament comprises a compound of Formula (I).
• the method can comprise administering to a patient in need of a treatment for diseases or disorders associated with modulation of PKR and/or PKM2 an effective amount of the compositions and/or compounds of Formula (I).
• the method can comprise the use of a PKR Activating Compound and/or a compound of Formula (I) in the preparation of a medicament for the treatment of diseases or disorders associated with modulation (e.g., activation) of PKR and/or PKM2.
• the present disclosure is directed to of the use of a PKR Activating Compound treating a disease or disorder associated with activation of PKR and/or PKM2.
• the use can comprise administering to a patient in need of a treatment for diseases or disorders associated with modulation of PKR and/or PKM2 an effective amount of the compositions and/or compounds of Formula (I).
• the disease or disorder is selected from the group consisting of SCD, sickle cell anemia, thalassemia (e.g., beta-thalassemia), hereditary non-spherocytic hemolytic anemia, hemolytic anemia (e.g., chronic hemolytic anemia caused by phosphoglycerate kinase deficiency), hereditary spherocytosis, hereditary elliptocytosis, abetalipoproteinemia (or Bassen-Kornzweig syndrome), paroxysmal nocturnal hemoglobinuria, acquired hemolytic anemia (e.g., congenital anemias (e.g., enzymopathies)), or anemia of chronic diseases.
• SCD sickle cell anemia
• thalassemia e.
• the present disclosure is directed to a method of activating PKR and/or PKM2.
• the method involves administering to a patient in need thereof an effective amount of a compound of Formula (I).
• the present disclosure is directed to a method of increasing the lifetime of red blood cells in a patient or ex vivo using an effective amount of a PKR Activating Compound, such as a compound of Formula (I), or to the use of a PKR Activating Compound, such as a compound of Formula (I), in the preparation of a medicament or a composition (e.g., reagent) for increasing the lifetime of red blood cells in a patient or ex vivo using an effective amount of a PKR Activating Compound, such as the compound Formula (I).
• a PKR Activating Compound such as a compound of Formula (I)
• a composition e.g., reagent
• the present disclosure is directed to a method of regulating 2,3- diphosphoglycerate levels in blood in a patient or ex vivo using an effective amount of a PKR Activating Compound, such as a compound Formula (I), or to the use of a PKR Activating Compound, such as a compound Formula (I), in the preparation of a medicament or a composition (e.g., reagent) for regulating 2,3-diphosphoglycerate levels in blood in a patient or ex vivo.
• a PKR Activating Compound such as a compound Formula (I)
• a composition e.g., reagent
• the present disclosure is directed to a method of regulating ATP levels in blood in a patient or ex vivo using an effective amount of a PKR Activating Compound, such as a compound Formula (I), or to the use of a PKR Activating Compound, such as a compound Formula (I), in the preparation of a medicament or a composition (e.g., reagent) for regulating ATP levels in blood in a patient or ex vivo.
• a PKR Activating Compound such as a compound Formula (I)
• a composition e.g., reagent
• the present disclosure relates to a method of treating a disease or disorder associated with decreased activity of PKR and/or PKM2 in a subject in need thereof, the method comprising administering to a patient in need thereof an effective amount of a compound of Formula (I).
• the disease or disorder is selected from the group consisting of PKD, SCD, sickle cell anemia, thalassemia (e.g., beta-thalassemia), hereditary non- spherocytic hemolytic anemia, hemolytic anemia (e.g., chronic hemolytic anemia caused by phosphoglycerate kinase deficiency), hereditary spherocytosis, hereditary elliptocytosis, abetalipoproteinemia (or Bassen-Kornzweig syndrome), paroxysmal nocturnal hemoglobinuria, acquired hemolytic anemia (e.g., congenital anemias (e.g., enzymopathies)), or anemia of chronic diseases.
• thalassemia e.g., beta-thalassemia
• hereditary non- spherocytic hemolytic anemia e.g., chronic hemolytic anemia caused by phosphoglycerate kinase deficiency
• the present disclosure relates to a compound of Formula (I) or a pharmaceutical composition
• a pharmaceutically acceptable carrier used for the treatment of SCD, sickle cell anemia, thalassemia (e.g., beta-thalassemia), hereditary non-spherocytic hemolytic anemia, hemolytic anemia (e.g., chronic hemolytic anemia caused by phosphoglycerate kinase deficiency), hereditary spherocytosis, hereditary elliptocytosis, abetalipoproteinemia (or Bassen-Kornzweig syndrome), paroxysmal nocturnal hemoglobinuria, acquired hemolytic anemia (e.g., congenital anemias (e.g., enzymopathies)), or anemia of chronic diseases.
• thalassemia e.g., beta-thalassemia
• hereditary non-spherocytic hemolytic anemia e.g., chronic hemolytic anemia caused by phospho
• compositions comprising a compound of Formula (I) and a pharmaceutically acceptable carrier.
• the present disclosure relates to a method of treating cancer.
• the method comprises administering to a patient in need of a treatment for cancer an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
• the present disclosure relates to a method for the manufacture of a medicament for treating a disease or condition mediated by PKR and/or PKM2, wherein the medicament comprises a compound of Formula (I).
• Compositions can be prepared according to conventional mixing, granulating or coating methods, respectively, and the present pharmaceutical compositions can contain from about 0.1% to about 99%, from about 5% to about 90%, or from about 1% to about 20% of the disclosed compound by weight or volume.
• the pharmaceutical acceptable carrier may further include an excipient, diluent, or surfactant.
• a pharmaceutically acceptable carrier such as a) a diluent, e.g., purified water, triglyceride oils, such as hydrogenated or partially hydrogenated vegetable oil, or mixtures thereof, corn oil, olive oil, sunflower oil, safflower oil, fish oils, such as EPA or DHA, or their esters or triglycerides or mixtures thereof, omega-3 fatty acids or derivatives thereof, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, sodium, saccharin, glucose and/or glycine; b) a lubricant, e.g., silica, talcum, stearic acid, its magnesium or calcium salt, sodium oleate, sodium stearate, magnesium stearate, sodium
• Parental injectable administration is generally used for subcutaneous, intramuscular or intravenous injections and infusions.
• Injectables can be prepared in conventional forms, either as liquid solutions or suspensions or solid forms suitable for dissolving in liquid prior to injection.
• Liquid, particularly injectable, compositions can, for example, be prepared by dissolution, dispersion, etc.
• the disclosed compound is dissolved in or mixed with a pharmaceutically acceptable solvent such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form an injectable isotonic solution or suspension.
• Proteins such as albumin, chylomicron particles, or serum proteins can be used to solubilize the disclosed compounds.
• the disclosed compounds can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.
• Liposomes can be formed from a variety of phospholipids, containing cholesterol, stearylamine or phosphatidylcholines.
• a film of lipid components is hydrated with an aqueous solution of drug to a form lipid layer encapsulating the drug, as described in U.S. Pat. No. 5,262,564 which is hereby incorporated by reference in its entirety.
• the disclosed compounds can be also formulated as a suppository that can be prepared from fatty emulsions or suspensions; using polyalkylene glycols such as propylene glycol, as the carrier.
• Disclosed compounds can also be delivered by the use of monoclonal antibodies as individual carriers to which the disclosed compounds are coupled.
• the disclosed compounds can also be coupled with soluble polymers as targetable drug carriers.
• Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol, polyhydroxyethylaspanamidephenol, or polyethyleneoxidepolylysine substituted with palmitoyl residues.
• the disclosed compounds can be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.
• a polymer e.g., a polycarboxylic acid polymer, or a polyacrylate.
• Administration of the disclosed compounds can be accomplished via any mode of administration for therapeutic agents. These modes include systemic or local administration such as oral, nasal, parenteral, transdermal, subcutaneous, vaginal, buccal, rectal or topical administration modes.
• systemic or local administration such as oral, nasal, parenteral, transdermal, subcutaneous, vaginal, buccal, rectal or topical administration modes.
• compositions can be in solid, semi-solid or liquid dosage form, such as, for example, injectables, tablets, suppositories, pills, time-release capsules, elixirs, tinctures, emulsions, syrups, powders, liquids, suspensions, or the like, sometimes in unit dosages and consistent with conventional pharmaceutical practices.
• injectables tablets, suppositories, pills, time-release capsules, elixirs, tinctures, emulsions, syrups, powders, liquids, suspensions, or the like, sometimes in unit dosages and consistent with conventional pharmaceutical practices.
• they can also be administered in intravenous (both bolus and infusion), intraperitoneal, subcutaneous or intramuscular form, and all using forms well known to those skilled in the pharmaceutical arts.
• the compounds of the present disclosure can be administered in effective amounts to treat a disease or disorder in subjects.
• the dosage regimen utilizing the disclosed compound is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal or hepatic function of the patient; and the particular disclosed compound employed.
• a physician or veterinarian of ordinary skill in the art can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.
• Effective dosage amounts of the disclosed compounds when used for the indicated effects, range from about 0.5 mg to about 5000 mg of the disclosed compound as needed to treat the condition.
• Compositions for in vivo or in vitro use can contain about 0.5, 5, 20, 50, 75, 100, 150, 250, 500, 750, 1000, 1250, 2500, 3500, or 5000 mg of the disclosed compound, or, in a range of from one amount to another amount in the list of doses.
• the compositions are in the form of a tablet that can be scored.
• Y is a bond,–(CR 5 R 5’ ) '
• each R 1 , R 1’ , R 2 , and R 2’ is independently–H,–(C 1 -C 6 )alkyl,–(C 2 -C 6 )alkenyl,–(C 2 - C 6 )alkynyl,–(C 3 -C 8 )cycloalkyl,–(C 4 -C 8 )cycloalkenyl, heterocyclyl, aryl, heteroaryl, halogen,– CN, –OR 5 , –SR 5 , –NO 2 , –NR 5 R 5’ , –S(O) 2 R 5 , –S(O) 2 NR 5 R 5’ , –S(O)R 5 , –S(O)NR 5 R 5’ , – NR 5 S(O) 2 R 5’ ,–NR 5 S(O)R 5’ ,–C(O)R 5 , or–C(O)OR 5 , wherein each alkyl, alkeny
• R 1 and R 1’ , or R 2 and R 2’ together with the atom to which they are attached, can combine to form–(C 3 -C 8 )cycloalkyl ring, heterocycle, (C 5 -C 8 )spirocycle or 5-to 8-membered spiroheterocycle;
• R 1 and R 2 together with the atoms to which they are attached, can combine to form a– (C 3 -C 8 )cycloalkyl or a 3-to 8-membered heterocycle;
• R 3 is independently –H, –(C 1 -C 6 )alkyl, –(C 2 -C 6 )alkenyl, –(C 2 -C 6 )alkynyl, –(C 3 - C 8 )cycloalkyl,–(C 4 -C 8 )cycloalkenyl, heterocyclyl, aryl, heteroaryl,–S(O) 2 R 5 ,–S(O) 2 NR 5 R 5’ ,– S(O)R 5 ,–S(O)NR 5 R 5’ ,–C(O)R 5 , or–C(O)OR 5 , wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more substituents selected from the group consisting of oxo, halogen,–CN,–R 5 ,–OR 5 ,
• R 2 and R 3 together with the atoms to which they are attached, can combine to form a 5- to 8-membered heterocyclic ring;
• R 1 and R 3 together with the atoms to which they are attached, can combine to form a 5- to 8-membered heterocyclic ring, optionally fused to an aryl or heteroaryl ring;
• R 4 is–H,–(C 1 -C 6 )alkyl,–(C 2 -C 6 )alkenyl,–(C 2 -C 6 )alkynyl,–(C 3 -C 8 )cycloalkyl,–(C 4 - C 8 )cycloalkenyl, heterocyclyl, aryl, heteroaryl, halogen,–CN,–OR 5 ,–SR 5 ,–NO 2 ,–NR 5 R 5’ ,– S(O) 2 R 5 ,–S(O) 2 NR 5 R 5’ ,–S(O)R 5 ,–S(O)NR 5 R 5’ ,–NR 5 S(O) 2 R 5’ ,–NR 5 S(O)R 5’ ,–C(O)R 5 , or– C(O)OR 5 , wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl,
• each R 5 and R 5' is independently, at each occurrence,–H,–(C 1 -C 6 )alkyl,–(C 2 -C 6 )alkenyl, –(C 2 -C 6 )alkynyl, –(C 3 -C 8 )cycloalkyl, –(C 4 -C 8 )cycloalkenyl, heterocyclyl, aryl, heteroaryl, halogen,–CN,–OR 6 ,–SR 6 ,–NO 2 ,–NR 6 R 6’ ,–S(O) 2 R 6 ,–S(O) 2 NR 6 R 6’ ,–S(O)R 6 ,–S(O)NR 6 R 6’ ,– NR 6 S(O) 2 R 6’ ,–NR 6 S(O)R 6’ ,–C(O)R 6 , or–C(O)OR 6 , wherein each alkyl, alkenyl, alkynyl, cycloal
• R 5 on adjacent atoms together with the atoms to which they are attached form an aryl ring optionally substituted with one or more R 6 ; or two R 5 on adjacent atoms together with the atoms to which they are attached form a heteroaryl ring optionally substituted with one or more R 6 ; or two R 5 on adjacent atoms together with the atoms to which they are attached form a (C 3 -C 8 )cycloalkyl ring optionally substituted with one or more R 6 ; or two R 5 on adjacent atoms together with the atoms to which they are attached form a heterocycloalkyl ring optionally substituted with one or more R 6 ;
• R 5' on adjacent atoms together with the atoms to which they are attached form an aryl ring optionally substituted with one or more R 6 ; or two R 5' on adjacent atoms together with the atoms to which they are attached form a heteroaryl ring optionally substituted with one or more R 6 ; or two R 5' on adjacent atoms together with the atoms to which they are attached form a (C 3 -C 8 )cycloalkyl ring optionally substituted with one or more R 6 ; or two R 5' on adjacent atoms together with the atoms to which they are attached form a heterocycloalkyl ring optionally substituted with one or more R 6 ;
• each R 6 and R 6' is independently, at each occurrence,–H,–(C 1 -C 6 )alkyl,–(C 2 -C 6 )alkenyl, –(C 2 -C 6 )alkynyl, –(C 3 -C 8 )cycloalkyl, –(C 4 -C 8 )cycloalkenyl, heterocyclyl, aryl, heteroaryl, halogen,–CN,–OR 7 ,–SR 7 ,–NO 2 ,–NR 7 R 7’ ,–S(O) 2 R 7 ,–S(O) 2 NR 7 R 7’ ,–S(O)R 7 ,–S(O)NR 7 R 7’ ,– NR 7 S(O) 2 R 7’ ,–NR 7 S(O)R 7’ ,–C(O)R 7 , or–C(O)OR 7 , wherein each alkyl, alkenyl, alkynyl, cycloal
• each R 7 and R 7' is independently, at each occurrence,–H,–(C 1 -C 6 )alkyl,–(C 2 -C 6 )alkenyl, –(C 2 -C 6 )alkynyl, –(C 3 -C 8 )cycloalkyl, –(C 4 -C 8 )cycloalkenyl, heterocyclyl, aryl, heteroaryl, halogen,–CN,–OH,–SH,–NO 2 ,–NH 2 ,–S(O) 2 H,–S(O) 2 NH 2 ,–S(O)H,–S(O)NH 2 ,–NHS(O) 2 H, –NHS(O)H, –C(O)H, or –C(O)OH, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, or heteroaryl is optionally
• t 0, 1, 2, or 3.
• R 1 and R 1’ are each independently hydrogen, optionally substituted–(C 1 -C 6 )alkyl, optionally substituted aryl, or optionally substituted heteroaryl, or wherein R 1 and R 1’ , taken together with the atoms to which they are attached, form an optionally substituted -(C 3 -C 4 )cycloalkyl.
• R 1 and R 1’ are each independently hydrogen or optionally substituted phenyl or pyridyl; R 2 and R 2’ are each independently hydrogen; and R 3 is hydrogen or optionally substituted -(C 1 -C 6 )alkyl.
• R 1 and R 1’ are each independently hydrogen or optionally substituted phenyl or pyridyl; R 2 and R 2’ are each independently hydrogen; and R 3 is hydrogen.
• Y is a bond,–(CR 5 R 5’ ) t –,–NR 5 (CR 5 R 5' ) t –, or–O—;
• R 1 is –(C 1 -C 6 )alkyl, –(C 2 -C 6 )alkenyl, –(C 2 -C 6 )alkynyl, –(C 3 -C 8 )cycloalkyl, –(C 4 - C 8 )cycloalkenyl, heterocyclyl, aryl, heteroaryl, halogen,–CN,–OR 5 ,–SR 5 ,–NO 2 ,–NR 5 R 5’ ,– S(O) 2 R 5 ,–S(O) 2 NR 5 R 5’ ,–S(O)R 5 ,–S(O)NR 5 R 5’ ,–NR 5 S(O) 2 R 5’ ,–NR 5 S(O)R 5’ ,–C(O)R 5 , or– C(O)OR 5 , wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycly
• each R 2 and R 2’ is independently–H,–(C 1 -C 6 )alkyl,–(C 2 -C 6 )alkenyl,–(C 2 -C 6 )alkynyl,– (C 3 -C 8 )cycloalkyl,–(C 4 -C 8 )cycloalkenyl, heterocyclyl, aryl, heteroaryl, halogen,–CN,–OR 5 ,– SR 5 ,–NO 2 ,–NR 5 R 5’ ,–S(O) 2 R 5 ,–S(O) 2 NR 5 R 5’ ,–S(O)R 5 ,–S(O)NR 5 R 5’ ,–NR 5 S(O) 2 R 5’ ,– NR 5 S(O)R 5’ , –C(O)R 5 , or —C(O)OR 5 , wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cyclo
• R 1 and R 2 together with the atoms to which they are attached, can combine to form a– (C 3 -C 8 )cycloalkyl or a 3-to 8-membered heterocycle;
• R 3 is independently –H, –(C 1 -C 6 )alkyl, –(C 2 -C 6 )alkenyl, –(C 2 -C 6 )alkynyl, –(C 3 - C 8 )cycloalkyl,–(C 4 -C 8 )cycloalkenyl, heterocyclyl, aryl, heteroaryl,–S(O) 2 R 5 ,–S(O) 2 NR 5 R 5’ ,– S(O)R 5 ,–S(O)NR 5 R 5’ ,–C(O)R 5 , or–C(O)OR 5 , wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more substituents selected from the group consisting of oxo, halogen,–CN,–R 5 ,–OR 5 ,
• R 2 and R 3 together with the atoms to which they are attached, can combine to form a 5- to 8-membered heterocyclic ring;
• R 1 and R 3 together with the atoms to which they are attached, can combine to form a 5- to 8-membered heterocyclic ring, optionally fused to an aryl or heteroaryl ring;
• R 4 is–H,–(C 1 -C 6 )alkyl,–(C 2 -C 6 )alkenyl,–(C 2 -C 6 )alkynyl,–(C 3 -C 8 )cycloalkyl,–(C 4 - C 8 )cycloalkenyl, heterocyclyl, aryl, heteroaryl, halogen,–CN,–OR 5 ,–SR 5 ,–NO 2 ,–NR 5 R 5’ ,– S(O) 2 R 5 ,–S(O) 2 NR 5 R 5’ ,–S(O)R 5 ,–S(O)NR 5 R 5’ ,–NR 5 S(O) 2 R 5’ ,–NR 5 S(O)R 5’ ,–C(O)R 5 , or– C(O)OR 5 , wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl,
• each R 5 and R 5' is independently, at each occurrence,–H,–(C 1 -C 6 )alkyl,–(C 2 -C 6 )alkenyl, –(C 2 -C 6 )alkynyl, –(C 3 -C 8 )cycloalkyl, –(C 4 -C 8 )cycloalkenyl, heterocyclyl, aryl, heteroaryl, halogen,–CN,–OR 6 ,–SR 6 ,–NO 2 ,–NR 6 R 6’ ,–S(O) 2 R 6 ,–S(O) 2 NR 6 R 6’ ,–S(O)R 6 ,–S(O)NR 6 R 6’ ,– NR 6 S(O) 2 R 6’ ,–NR 6 S(O)R 6’ ,–C(O)R 6 , or–C(O)OR 6 , wherein each alkyl, alkenyl, alkynyl, cycloal
• R 5 on adjacent atoms together with the atoms to which they are attached form an aryl ring optionally substituted with one or more R 6 ; or two R 5 on adjacent atoms together with the atoms to which they are attached form a heteroaryl ring optionally substituted with one or more R 6 ; or two R 5 on adjacent atoms together with the atoms to which they are attached form a (C 3 -C 8 )cycloalkyl ring optionally substituted with one or more R 6 ; or two R 5 on adjacent atoms together with the atoms to which they are attached form a heterocycloalkyl ring optionally substituted with one or more R 6 ;
• R 5' on adjacent atoms together with the atoms to which they are attached form an aryl ring optionally substituted with one or more R 6 ; or two R 5' on adjacent atoms together with the atoms to which they are attached form a heteroaryl ring optionally substituted with one or more R 6 ; or two R 5' on adjacent atoms together with the atoms to which they are attached form a (C 3 -C 8 )cycloalkyl ring optionally substituted with one or more R 6 ; or two R 5' on adjacent atoms together with the atoms to which they are attached form a heterocycloalkyl ring optionally substituted with one or more R 6 ;
• each R 6 and R 6' is independently, at each occurrence,–H,–(C 1 -C 6 )alkyl,–(C 2 -C 6 )alkenyl, –(C 2 -C 6 )alkynyl, –(C 3 -C 8 )cycloalkyl, –(C 4 -C 8 )cycloalkenyl, heterocyclyl, aryl, heteroaryl, halogen,–CN,–OR 7 ,–SR 7 ,–NO 2 ,–NR 7 R 7’ ,–S(O) 2 R 7 ,–S(O) 2 NR 7 R 7’ ,–S(O)R 7 ,–S(O)NR 7 R 7’ ,– NR 7 S(O) 2 R 7’ ,–NR 7 S(O)R 7’ ,–C(O)R 7 , or–C(O)OR 7 , wherein each alkyl, alkenyl, alkynyl, cycloal
• each R 7 and R 7' is independently, at each occurrence,–H,–(C 1 -C 6 )alkyl,–(C 2 -C 6 )alkenyl, –(C 2 -C 6 )alkynyl, –(C 3 -C 8 )cycloalkyl, –(C 4 -C 8 )cycloalkenyl, heterocyclyl, aryl, heteroaryl, halogen,–CN,–OH,–SH,–NO 2 ,–NH 2 ,–S(O) 2 H,–S(O) 2 NH 2 ,–S(O)H,–S(O)NH 2 ,–NHS(O) 2 H, –NHS(O)H, –C(O)H, or –C(O)OH, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, or heteroaryl is optionally
• t 0, 1, 2, or 3.
• R 1 is optionally substituted– (C 1 -C 6 )alkyl, optionally substituted aryl, or optionally substituted heteroaryl.
• R 1 is optionally substituted phenyl or pyridyl
• R 2 and R 2’ are each independently hydrogen
• R 3 is hydrogen or optionally substituted -(C 1 -C 6 )alkyl.
• Y is a bond,–(CR 5 R 5’ ) 5
• R 1 is –(C 1 -C 6 )alkyl, –(C 2 -C 6 )alkenyl, –(C 2 -C 6 )alkynyl, –(C 3 -C 8 )cycloalkyl, –(C 4 - C 8 )cycloalkenyl, heterocyclyl, aryl, heteroaryl, halogen,–CN,–OR 5 ,–SR 5 ,–NO 2 ,–NR 5 R 5’ ,– S(O) 2 R 5 ,–S(O) 2 NR 5 R 5’ ,–S(O)R 5 ,–S(O)NR 5 R 5’ ,–NR 5 S(O) 2 R 5’ ,–NR 5 S(O)R 5’ ,–C(O)R 5 , or– C(O)OR 5 , wherein each alkyl, alkenyl, al
• each R 2 and R 2’ is independently–H,–(C 1 -C 6 )alkyl,–(C 2 -C 6 )alkenyl,–(C 2 -C 6 )alkynyl,– (C 3 -C 8 )cycloalkyl,–(C 4 -C 8 )cycloalkenyl, heterocyclyl, aryl, heteroaryl, halogen,–CN,–OR 5 ,– SR 5 ,–NO 2 ,–NR 5 R 5’ ,–S(O) 2 R 5 ,–S(O) 2 NR 5 R 5’ ,–S(O)R 5 ,–S(O)NR 5 R 5’ ,–NR 5 S(O) 2 R 5’ ,– NR 5 S(O)R 5’ , –C(O)R 5 , or —C(O)OR 5 , wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cyclo
• R 1 and R 2 together with the atoms to which they are attached, can combine to form a– (C 3 -C 8 )cycloalkyl or a 3-to 8-membered heterocycle;
• R 3 is independently –H, –(C 1 -C 6 )alkyl, –(C 2 -C 6 )alkenyl, –(C 2 -C 6 )alkynyl, –(C 3 - C 8 )cycloalkyl,–(C 4 -C 8 )cycloalkenyl, heterocyclyl, aryl, heteroaryl,–S(O) 2 R 5 ,–S(O) 2 NR 5 R 5’ ,– S(O)R 5 ,–S(O)NR 5 R 5’ ,–C(O)R 5 , or–C(O)OR 5 , wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more substituents selected from the group consisting of oxo, halogen,–CN,–R 5 ,–OR 5 ,
• R 2 and R 3 together with the atoms to which they are attached, can combine to form a 5- to 8-membered heterocyclic ring;
• R 1 and R 3 together with the atoms to which they are attached, can combine to form a 5- to 8-membered heterocyclic ring, optionally fused to an aryl or heteroaryl ring;
• R 4 is—H,–(C 1 -C 6 )alkyl,–(C 2 -C 6 )alkenyl,–(C 2 -C 6 )alkynyl,–(C 3 -C 8 )cycloalkyl,–(C 4 - C 8 )cycloalkenyl, heterocyclyl, aryl, heteroaryl, halogen,–CN,–OR 5 ,–SR 5 ,–NO 2 ,–NR 5 R 5’ ,– S(O) 2 R 5 ,–S(O) 2 NR 5 R 5’ ,–S(O)R 5 ,–S(O)NR 5 R 5’ ,–NR 5 S(O) 2 R 5’ ,–NR 5 S(O)R 5’ ,–NR 5
• each R 5 and R 5' is independently, at each occurrence,–H,–(C 1 -C 6 )alkyl,–(C 2 -C 6 )alkenyl, –(C 2 -C 6 )alkynyl, –(C 3 -C 8 )cycloalkyl, –(C 4 -C 8 )cycloalkenyl, heterocyclyl, aryl, heteroaryl, halogen,–CN,–OR 6 ,–SR 6 ,–NO 2 ,–NR 6 R 6’ ,–S(O) 2 R 6 ,–S(O) 2 NR 6 R 6’ ,–S(O)R 6 ,–S(O)NR 6 R 6’ ,– NR 6 S(O) 2 R 6’ ,–NR 6 S(O)R 6’ ,–C(O)R 6 , or–C(O)OR 6 , wherein each alkyl, alkenyl, alkynyl, cycloal
• R 5 on adjacent atoms together with the atoms to which they are attached form an aryl ring optionally substituted with one or more R 6 ; or two R 5 on adjacent atoms together with the atoms to which they are attached form a heteroaryl ring optionally substituted with one or more R 6 ; or two R 5 on adjacent atoms together with the atoms to which they are attached form a (C 3 -C 8 )cycloalkyl ring optionally substituted with one or more R 6 ; or two R 5 on adjacent atoms together with the atoms to which they are attached form a heterocycloalkyl ring optionally substituted with one or more R 6 ;
• each R 6 and R 6' is independently, at each occurrence,–H,–(C 1 -C 6 )alkyl,–(C 2 -C 6 )alkenyl, –(C 2 -C 6 )alkynyl, –(C 3 -C 8 )cycloal
• each R 7 and R 7' is independently, at each occurrence,–H,–(C 1 -C 6 )alkyl,–(C 2 -C 6 )alkenyl, –(C 2 -C 6 )alkynyl, –(C 3 -C 8 )cycloalkyl, –(C 4 -C 8 )cycloalkenyl, heterocyclyl, aryl, heteroaryl, halogen,–CN,–OH,–SH,–NO 2 ,–NH 2 ,–S(O) 2 H,–S(O) 2 NH 2 ,–S(O)H,–S(O)NH 2 ,–NHS(O) 2 H, –NHS(O)H, –C(O)H, or –C(O)OH, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, or heteroaryl is optionally
• t 0, 1, 2, or 3.
• a pharmaceutical composition comprising a compound of any one of embodiments 1-61 and a pharmaceutically acceptable carrier.
• a method of treating a disease or disorder associated with modulation of pyruvate kinase comprising administering to a patient in need thereof an effective amount of a compound of any one of embodiments 1-61 or a composition of embodiment 62.
• a method of treating a disease associated with decreased activity of PKR in a subject in need thereof comprising administering to the subject an effective amount of a compound of any one of embodiments 1-61 or a composition of embodiment 62.
• a method of activating PKR comprising administering to a subject in need thereof an effective amount of a compound of any one of embodiments 1-61 or a composition of embodiment 62.
• a method of increasing the lifetime of red blood cells comprising administering to a subject in need thereof an effective amount of a compound of any one of embodiments 1-61 or a composition of embodiment 62.
• a method of regulating 2,3-diphosphoglycerate levels in blood comprising administering to a subject in need thereof an effective amount of a compound of any one of embodiments 1-61 or a composition of embodiment 62.
• a method of regulating ATP levels in blood comprising administering to a subject in need thereof an effective amount of a compound of any one of embodiments 1-61 or a composition of embodiment 62.
• a method of treating hereditary non-spherocytic hemolytic anemia comprising administering to a subject in need thereof an effective amount of a compound of any one of embodiments 1-61 or a composition of embodiment 62.
• 70. A method of treating a disease or disorder associated with increased 2,3- diphosphoglycerate levels comprising administering to a subject in need thereof an effective amount of a compound of any one of embodiments 1-61 or a composition of embodiment 62.
• 71. A method of a treating disease or disorder associated with decreased ATP levels comprising administering to a subject in need thereof an effective amount of a compound of any one of embodiments 1-61 or a composition of embodiment 62.
• the disease or disorder is selected from the group consisting of sickle cell disease, sickle cell anemia, thalassemia (e.g., beta-thalassemia), hereditary non-spherocytic hemolytic anemia, hemolytic anemia (e.g., chronic hemolytic anemia caused by phosphoglycerate kinase deficiency), hereditary spherocytosis, hereditary elliptocytosis, abetalipoproteinemia (or Bassen-Kornzweig syndrome), paroxysmal nocturnal hemoglobinuria, acquired hemolytic anemia (e.g., congenital anemias (e.g., enzymopathies)), and anemia of chronic diseases.
• thalassemia e.g., beta-thalassemia
• hereditary non-spherocytic hemolytic anemia e.g., chronic hemolytic anemia caused by phosphoglycerate kinase deficiency
• a method of treating a disease or disorder comprising administering to a patient in need thereof an effective amount of a compound of any one of embodiments 1-61 or a composition of embodiment 62.
• the disease or disorder is selected from the group consisting of sickle cell disease, sickle cell anemia, thalassemia (e.g., beta-thalassemia), hereditary non-spherocytic hemolytic anemia, hemolytic anemia (e.g., chronic hemolytic anemia caused by phosphoglycerate kinase deficiency), hereditary spherocytosis, hereditary elliptocytosis, abetalipoproteinemia (or Bassen-Kornzweig syndrome), paroxysmal nocturnal hemoglobinuria, acquired hemolytic anemia (e.g., congenital anemias (e.g., enzymopathies)), and anemia of chronic diseases.
• thalassemia e.g., beta-thalassemia
• hereditary non-spherocytic hemolytic anemia e.g., chronic hemolytic anemia caused by phosphoglycerate kinase deficiency
• Step 1.2H,3H-[1,4]dioxino[2,3-b]pyridine-7-sulfonyl chloride Into a 100 mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen was placed a solution of n-BuLi in hexane (2.5 M, 2 mL, 5.0 mmol, 0.54 equiv) and a solution of n-Bu 2 Mg in heptanes (1.0 M, 4.8 mL, 4.8 mmol, 0.53 equiv). The resulting solution was stirred for 10 min at RT (20 °C).
• Step2 tert-butyl 5-(2,3-dihydro-1,4-benzodioxine-6-sulfonyl)- 1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrole-2-carboxylate
• tert-butyl 5-(2,3-dihydro-1,4-benzodioxine-6- sulfonyl)-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrole-2-carboxylate as a brown solid.
• Step 3 2-(2,3-dihydro-1,4-benzodioxine-6-sulfonyl)-1H,2H,3H,4H,5H,6H- pyrrolo[3,4-c]pyrrole
• Step 1 tert-Butyl 5-(benzofuran-5-ylsulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4- c]pyrrole-2(1H)-carboxylate
• Step 1 tert-Butyl 5-(pyridine-2-sulfonyl)-1H,2H,3H,4H,5H,6H-pyrrolo[3,4- c]pyrrole-2-carboxylate.
• Step 1 2-Bromo-N-(2-hydroxyphenyl)-2-methylpropanamide
• 2-aminophenol 5 g, 45.82 mmol, 1.00 equiv
• THF 150 mL
• TEA 5.1 g, 50.40 mmol
• 2-Bromo-2- methylpropanoyl bromide (11.6 g, 50.46 mmol, 1.10 equiv) was then added dropwise.
• the solution was stirred for 1 h at 0 °C.
• the reaction was then quenched by the addition of water (15 mL).
• Step 4 2,2-Dimethyl-3,4-dihydro-2H-1,4-benzoxazine-6-sulfonyl chloride
• 2,2-Dimethyl-3,4-dihydro-2H-1,4-benzoxazine 500 mg, 3.06 mmol, 1.00 equiv
• Sulfurochloridic acid 5 g, 42.91 mmol, 14.01 equiv
• the solution was stirred for 2 h at 60 °C.
• Step 5 tert-Butyl 5-(2,2-dimethyl-3,4-dihydro-2H-1,4-benzoxazine-6-sulfonyl)- 1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrole-2-carboxylate
• the resulting solution was stirred overnight at 20 °C.
• the reaction mixture was diluted with 20 mL of water and was then extracted with 3x20 mL of dichloromethane. The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum.
• the residue was purified by prep-TLC eluted with dichloromethane/methanol (20:1) and further purified by prep-HPLC (Column: XBridge C18 OBD Prep Column, 100 ⁇ , 5 ⁇ m, 19 mm x 250 mm; Mobile Phase A: water (10 mmol/L NH 4 HCO 3 ), Mobile Phase B: MeCN; Gradient: 15% B to 45% B over 8 min; Flow rate: 20 mL/min; UV Detector: 254 nm).
• LC-MS (ESI) m/z: calculated for C 22 H 23 N 3 O 6 S: 457.13; found: 458.0 [M+H] + .
• Examples 3 and 4 (2S or 2R)-1-(5-[2H,3H-[1,4]dioxino[2,3-b]pyridine-7- sulfonyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl)-3-hydroxy-2-(pyridin-2- yl)propan-1-one (Example 4) and (2R or 2S)-1-(5-[2H,3H-[1,4]dioxino[2,3-b]pyridine-7- sulfonyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl)-3-hydroxy-2-(pyridin-2- yl)propan-1-one (Example 3)
• Examples 5 and 6 (R or S)-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7- yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)(tetrahydro-2H-pyran-3- yl)methanone (Example 5) and (S or R)-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7- yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)(tetrahydro-2H-pyran-3- yl)methanone (Example 6)
• the residue was purified by silica gel chromatography eluted with dichloromethane/methanol (20:1) and further purified by prep-HPLC (Column: XBridge BEH C18 OBD Prep Column, 130 ⁇ , 5 ⁇ m, 19 mm x 150 mm; Mobile phase: water (10 mmol NH 4 HCO 3 ), MeCN (1% MeCN up to 40% over 8 min); Flow rate: 20 mL/min; Detector: 254 & 220 nm).
• Example 5 1 H NMR (400 MHz, CDCl 3 ): ⁇ 8.31 (s, 1H), 7.60 (s, 1H), 4.57-4.50 (m, 2H), 4.36-4.25 (m, 4H), 4.15-4.09 (m, 6H), 3.94-3.88 (m, 2H), 3.56-3.50 (m, 1H), 3.49-3.33 (m, 1H), 2.63-2.60 (m, 1H), 1.95-1.78 (m, 2H), 1.67-1.61 (m, 2H).
• Example 6 1 H NMR (400 MHz, CDCl 3 ): ⁇ 8.30 (s, 1H), 7.61 (s, 1H), 4.54-4.52 (m, 2H), 4.35-4.27 (m, 4H), 4.15-4.09 (m, 6H), 3.95-3.90 (m, 2H), 3.56-3.50 (m, 1H), 3.42-3.35 (m, 1H), 2.65-2.60 (m, 1H), 1.95-1.78 (m, 2H), 1.67-1.62 (m, 2H).
• Example 7 1-(5-[[4-(Difluoromethoxy)benzene]sulfonyl]-1H,2H,3H,4H,5H,6H- pyrrolo[3,4-c]pyrrol-2-yl)-3-hydroxy-2,2-dimethylpropan-1-one
• Example 19 1-(5-(Benzo[d]thiazol-6-ylsulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4- c]pyrrol-2(1H)-yl)-3-hydroxy-2,2-dimethylpropan-1-one
• Example 26 (2S,3R and 2R,3S)-1-(5-[[4-(difluoromethoxy)benzene]sulfonyl]- 1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl)-3-hydroxy-2-phenylbutan-1-one
• Example 32 (2S)-1-[5-(2,2-dimethyl-3,4-dihydro-2H-1,4-benzoxazine-6- sulfonyl)-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl]-3-hydroxy-2-phenylpropan-1-one
• Examples 33 and 34 6-(5-[[(3S or 3R)-oxan-3-yl]carbonyl]-1H,2H,3H,4H,5H,6H- pyrrolo[3,4-c]pyrrole-2-sulfonyl)-3,4-dihydro-2H-1,4-benzoxazine (Example 33) and 6-(5- [[(3R or 3S)-oxan-3-yl]carbonyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrole-2-sulfonyl)- 3,4-dihydro-2H-1,4-benzoxazine (Example 34)
• oxane-3-carboxylic acid (62.4 mg, 0.48 mmol, 1.20 equiv), DIEA (154.8 mg, 1.20 mmol, 3.00 equiv), 1-(6-((3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)sulfonyl)-2,3-dihydro-4H- benzo[b][1,4]oxazin-4-yl)ethan-1-one hydrochloride salt (154.4 mg, 0.40 mmol, 1.00 equiv), HATU (167.2 mg, 0.44 mmol, 1.10 equiv), and dichloromethane (4 ml).
• the crude product (100 mg) was further purified by Prep- HPLC (Column: Xbridge Prep C18 5 ⁇ m 19x150mm; mobile phase: water (contains 0.05% NH 3 ⁇ H 2 O) and CH 3 CN with a gradient of 16% to 34% CH 3 CN in 10 min; detector UV wave length 220 & 254 nm) to provide 80 mg (96%) of 6-[5-[(oxan-3-yl)carbonyl]- 1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrole-2-sulfonyl]-3,4-dihydro-2H-1,4-benzoxazine as a white solid.
• Step 3 Examples 33 and 34: 6-(5-[[(3S or 3R) -oxan-3-yl]carbonyl]- 1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrole-2-sulfonyl)-3,4-dihydro-2H-1,4-benzoxazine and 6-(5-[[(3R or 3S)-oxan-3-yl]carbonyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrole-2- sulfonyl)-3,4-dihydro-2H-1,4-benzoxazine [00225] Chiral separation of racemic 6-[5-[(oxan-3-yl)carbonyl]-1H,2H,3H,4H,5H,6H- pyrrolo[3,4-c]pyrrole-2-sulfonyl]-3,4-d
• Examples 41 and 42 (S or R-)-1-(5-(4-(Difluoromethoxy)phenylsulfonyl)-4,5- dihydropyrrolo[3,4-c]pyrrol-2(1H,3H,4H)-yl)-3-hydroxy-2-(pyridin-2-yl)propan-1-one (Example 41) and (R or S)-1-(5-(4-(difluoromethoxy)phenylsulfonyl)-4,5- dihydropyrrolo[3,4-c]pyrrol-2(1H,3H,4H)-yl)-3-hydroxy-2-(pyridin-2-yl)propan-1-one (Example 42)
• the enantiomers were separated by Chiral-Prep-HPLC (SHIMADZU LC-20AD) with the following conditions: Column, DAICEL chiral PAK OD-H, 20x250mm, 5 ⁇ m; mobile phase: Phase A: ethanol, Phase B: methanol (containing 0.1% DEA) with isocratic elution of 60% ethanol; flow rate: 15mL/min; detector wavelength: 220 nm. Absolute stereochemistry was not determined (*). This provided:
• Example 41 (S or R)-1-(5-(4-(Difluoromethoxy)phenylsulfonyl)-4,5- dihydropyrrolo[3,4-c]pyrrol-2(1H,3H,4H)-yl)-3-hydroxy-2-(pyridin-2-yl)propan-1-one Isolated as a yellow solid (11.3 mg, 15%).
• Example 42 (R or S)-1-(5-(4-(Difluoromethoxy)phenylsulfonyl)-4,5- dihydropyrrolo[3,4-c]pyrrol-2(1H,3H,4H)-yl)-3-hydroxy-2-(pyridin-2-yl)propan-1-one Isolated as a yellow solid (14.2 mg, 19%).
• Example 43 (5-(Benzo[d]thiazol-6-ylsulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4- c]pyrrol-2(1H)-yl)(2,3-dihydrobenzofuran-3-yl)methanone
• Examples 44 and 45 (R or S)-(5-(pyridin-2-ylsulfonyl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)(tetrahydro-2H-pyran-3-yl)methanone (Example 44) and (S or R)-(5-(pyridin-2-ylsulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)- yl)(tetrahydro-2H-pyran-3-yl)methanone (Example 45)
• Example 44 (R or S)-(5-(pyridin-2-ylsulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4- c]pyrrol-2(1H)-yl)(tetrahydro-2H-pyran-3-yl)methanone (stereochemical configuration assumed).
• Example 45 (S or R)-(5-(pyridin-2-ylsulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4- c]pyrrol-2(1H)-yl)(tetrahydro-2H-pyran-3-yl)methanone (stereochemical configuration assumed).
• Example 46 3-Hydroxy-1-(5-((4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-6- yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-2-phenylpropan-1-one
• the reaction was heated at 50 °C with shaking for 2 hours.4 M HCl in dioxane (50.0 ⁇ L, 0.200 mmol) was then added. The reaction was heated at 50 °C with shaking for an additional 2 hours. The volatiles were removed under reduced pressure. ACN (200 ⁇ L) was added to the vial. The vial was shaken for 15 minutes to resuspend the residue. Neat DIEA (25 ⁇ L, 0.143 mmol) and a 0.2 M solution of 3-hydroxy-2-phenylpropanoic acid (110 ⁇ L, 22 ⁇ mol) in dioxane was added to the vial, followed by a 0.2 M solution of HBTU (110 ⁇ L, 22 ⁇ mol) in ACN.
• a“PKR Activating Compound” refers to a compound having one or more characteristics when tested according to the following Luminescence Assay Protocol of Example 47 performed with wild type (wt) PKR and/or any one or more of G332S mutant form of PKR or R510Q mutant form of PKR: (1) an AC 50 value of less than 40 ⁇ M (e.g., compounds with AC 50 values of “+”,“++”, or“+++” in Table 6); (2) a maximum % Fold (MAX%Fold) value of greater than 75%; and/or (3) a % Fold value at 1.54 ⁇ M compound concentration (%Fold@1.54 ⁇ M) of at least 75%.
• a PKR Activating Compound can have: (1) an AC 50 value of less than 0.1 ⁇ M (e.g., compounds with AC 50 values of“+++” in Table 6), 0.1-1.0 ⁇ M (e.g., compounds with AC 50 values of“++” in Table 6), or 1.01-40 ⁇ M (e.g., compounds with AC 50 values of“+” in Table 6); (2) a MAX%Fold of 75%- 250%, 250-500%, or 75%-500%; and/or (3) a %Fold@1.54 ⁇ M of 75%-250%, 250-500%, or 75%-500%.
• a PKR Activating Compound has (1) an AC 50 value of less than 1.0 ⁇ M; (2) a MAX%Fold of 75%-500%; and/or (3) a %Fold@1.54 ⁇ M of 75%-500%, obtained in the Luminescence Assay Protocol with any one or more of wild type PKR (wt), G332S mutant form of PKR, or R510Q mutant form of PKR.
• the PKR Activating Compound has (1) an AC 50 value of less than 1.0 ⁇ M; (2) a MAX%Fold of 75%- 500%; and/or (3) a %Fold@1.54 ⁇ M of 75%-500%, obtained in the Luminescence Assay Protocol with wild type PKR (wt). In some embodiments, the PKR Activating Compound has (1) an AC 50 value of less than 1.0 ⁇ M; (2) a MAX%Fold of 75%-500%; and/or (3) a %Fold@1.54 ⁇ M of 75%-500%, obtained in the Luminescence Assay Protocol with any one or both of G332S mutant form of PKR or R510Q mutant form of PKR.
• ADP Adenosine-5'-diphosphate
• Enzyme and PEP [Phospho(enol) pyruvic acid] were added at 2x to all wells of an assay-ready plate containing serial dilutions of test compounds or DMSO vehicle.
• Final enzyme concentrations for PKR(wt), PKR(R510Q), and PKR(G332S) were 0.8 nM, 0.8 nM, and 10 nM respectively.
• Final PEP concentration was 100 ⁇ M.
• the Enzyme/PEP mixture was incubated with compounds for 30 minutes at RT before the assay was initiated with the addition of 2x ADP [Adenosine-5'-diphosphate] and KinaseGloPlus. Final concentration of ADP was 100 ⁇ M.
• Luminescence values were converted to % Fold increase by normalizing to the average of the DMSO control and multiplying by 100.
• Max, min, slope and AC 50 were determined by the standard four parameter fit algorithm of ActivityBase XE Runner. Compounds were evaluated with three parameters - AC 50 , MAX%Fold, and %Fold@1.54 ⁇ M (FIG. 1).
• the AC 50 value for a compound is the concentration ( ⁇ M) corresponding to the midway between the maximum and minimum values of the four parameter logistic curve fit (i.e., at which the % fold increase along the four parameter logistic curve fit is halfway between MAX%Fold and MIN%Fold (% Fold Midpoint)), MAX%Fold is the highest fold increase observed at any concentration of compound, and %Fold@1.54 ⁇ M is the fold increase at a compound concentration of 1.54 ⁇ M.
• the parameter %Fold@1.54 ⁇ M was selected to capture elements of both the AC 50 and MAX%Fold and to provide a ranking based on both potency and effect.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Epidemiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Hematology (AREA)
• Diabetes (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Nutrition Science (AREA)
• Physiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
• Pyridine Compounds (AREA)
• Medicinal Preparation (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Priority Applications (42)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=61911726

Family Applications (1)

Country Status (32)

Cited By (14)

Families Citing this family (18)

Citations (5)

Family Cites Families (357)

• 2018
  • 2018-03-20 ES ES18716455T patent/ES2747768T3/es active Active
  • 2018-03-20 TW TW111128139A patent/TWI887559B/zh active
  • 2018-03-20 MA MA050589A patent/MA50589A/fr unknown
  • 2018-03-20 DK DK18209919.2T patent/DK3483164T3/da active
  • 2018-03-20 LT LT18716455T patent/LT3448859T/lt unknown
  • 2018-03-20 HU HUE18209919A patent/HUE049979T2/hu unknown
  • 2018-03-20 US US15/926,236 patent/US10208052B1/en active Active
  • 2018-03-20 WO PCT/US2018/023405 patent/WO2018175474A1/en not_active Ceased
  • 2018-03-20 MD MDE20190592T patent/MD3483164T2/ro unknown
  • 2018-03-20 EP EP20158204.6A patent/EP3680241A1/en not_active Withdrawn
  • 2018-03-20 CN CN202110722793.8A patent/CN113456634A/zh active Pending
  • 2018-03-20 MX MX2020013936A patent/MX2020013936A/es unknown
  • 2018-03-20 JP JP2018560074A patent/JP6594570B2/ja active Active
  • 2018-03-20 SM SM20190517T patent/SMT201900517T1/it unknown
  • 2018-03-20 CN CN201880002215.3A patent/CN109311897B/zh active Active
  • 2018-03-20 EA EA201992215A patent/EA201992215A1/ru unknown
  • 2018-03-20 SM SM20200243T patent/SMT202000243T1/it unknown
  • 2018-03-20 TW TW107109420A patent/TWI772389B/zh active
  • 2018-03-20 AU AU2018240172A patent/AU2018240172C1/en active Active
  • 2018-03-20 MA MA44795A patent/MA44795B1/fr unknown
  • 2018-03-20 NZ NZ763766A patent/NZ763766A/en unknown
  • 2018-03-20 PT PT182099192T patent/PT3483164T/pt unknown
  • 2018-03-20 SG SG11201908670S patent/SG11201908670SA/en unknown
  • 2018-03-20 US US16/496,279 patent/US11014927B2/en active Active
  • 2018-03-20 RU RU2018139648A patent/RU2707751C1/ru active
  • 2018-03-20 MX MX2018014032A patent/MX378512B/es unknown
  • 2018-03-20 ES ES18209919T patent/ES2788856T3/es active Active
  • 2018-03-20 KR KR1020187035080A patent/KR102007135B1/ko active Active
  • 2018-03-20 RU RU2019137023A patent/RU2736217C2/ru active
  • 2018-03-20 PL PL18716455T patent/PL3448859T3/pl unknown
  • 2018-03-20 MD MDE20190287T patent/MD3448859T2/ro unknown
  • 2018-03-20 HR HRP20191665TT patent/HRP20191665T1/hr unknown
  • 2018-03-20 DK DK18716455.3T patent/DK3448859T3/da active
  • 2018-03-20 AR ARP180100641A patent/AR111295A1/es active IP Right Grant
  • 2018-03-20 RS RSP20191212 patent/RS59306B1/sr unknown
  • 2018-03-20 EP EP18209919.2A patent/EP3483164B1/en active Active
  • 2018-03-20 NZ NZ748072A patent/NZ748072A/en unknown
  • 2018-03-20 KR KR1020197022135A patent/KR102296703B1/ko active Active
  • 2018-03-20 RS RS20200509A patent/RS60209B1/sr unknown
  • 2018-03-20 TN TNP/2020/000045A patent/TN2020000045A1/en unknown
  • 2018-03-20 TN TNP/2019/000290A patent/TN2019000290A1/en unknown
  • 2018-03-20 MA MA45614A patent/MA45614B1/fr unknown
  • 2018-03-20 PT PT187164553T patent/PT3448859T/pt unknown
  • 2018-03-20 CA CA3024181A patent/CA3024181C/en active Active
  • 2018-03-20 EP EP18716455.3A patent/EP3448859B1/en active Active
  • 2018-03-20 PL PL18209919T patent/PL3483164T3/pl unknown
  • 2018-03-20 SI SI201830038T patent/SI3483164T1/sl unknown
  • 2018-03-20 SI SI201830005T patent/SI3448859T1/sl unknown
  • 2018-03-20 LT LTEP18209919.2T patent/LT3483164T/lt unknown
  • 2018-03-20 HU HUE18716455A patent/HUE045261T2/hu unknown
• 2019
  • 2019-01-11 US US16/245,654 patent/US10472371B2/en active Active
  • 2019-07-16 AU AU2019206013A patent/AU2019206013B2/en active Active
  • 2019-08-16 JP JP2019149316A patent/JP7213775B2/ja active Active
  • 2019-08-21 AR ARP190102376A patent/AR115993A2/es unknown
  • 2019-09-19 IL IL269447A patent/IL269447B/en unknown
  • 2019-09-19 SA SA519410164A patent/SA519410164B1/ar unknown
  • 2019-09-23 ZA ZA2019/06278A patent/ZA201906278B/en unknown
  • 2019-10-04 US US16/593,523 patent/US10836771B2/en active Active
  • 2019-10-08 CY CY20191101055T patent/CY1122393T1/el unknown
• 2020
  • 2020-05-08 HR HRP20200752TT patent/HRP20200752T1/hr unknown
  • 2020-05-18 CY CY20201100452T patent/CY1123897T1/el unknown
  • 2020-10-02 US US17/062,059 patent/US11396513B2/en active Active
  • 2020-11-06 RU RU2020136402A patent/RU2020136402A/ru unknown
• 2021
  • 2021-02-25 AU AU2021201244A patent/AU2021201244B2/en not_active Ceased
  • 2021-04-23 US US17/239,364 patent/US11649242B2/en active Active
  • 2021-12-20 IL IL289175A patent/IL289175A/en unknown
• 2022
  • 2022-09-28 AU AU2022241506A patent/AU2022241506A1/en not_active Withdrawn
• 2023
  • 2023-03-21 US US18/124,071 patent/US12071440B2/en active Active
• 2024
  • 2024-07-17 US US18/775,532 patent/US20240391922A1/en active Pending

Patent Citations (5)